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Abstract 
Oxidative stress is an imbalance between the amount of oxidants and antioxidants in favour of 
the oxidants. Thus, when there is excessive production of reactive oxygen species (ROS) or 
antioxidant defence mechanisms are diminished, oxidative stress occurs. In order to maintain 
normal cellular functioning any excess of ROS must be continuously inactivated through the use of 
antioxidants.1,2 
Phenolic amino acids, such as tyrosine, exhibit a wide range of biological activities and have 
shown to be effective antioxidants in different in vitro antioxidant activities studies. Phenolic acids 
coupled with amino acids are involved in suppressing the adverse effects of oxidative stress and 
have a wide range of biological activities, such as antioxidant,3 anticancer4 and antimicrobial.5  
In this work a strategy based on the Ugi reaction was developed for the synthesis of new 
phenolic amino acids. Hydroxybenzaldehyde derivatives were reacted with 4-methoxybenzylamine, 
cyclohexyl isocyanide and benzoic acid, phenolic acids or catecholic acids to give Ugi adducts that 
were treated with trifluoroacetic acid, yielding N-acyl (hydroxyphenyl)glycine amides in good yields. 
The use of N-benzyloxycarbonylglycine as acid component allowed the preparation of a 3,4-
dihydroxyphenylglycyl dipeptide derivative. Radical-scavenging activity studies of the polyphenolic 
amino acid derivatives showed a sharp increase in activity with the increase in number of hydroxyl 
or catechol groups present.  
Several studies suggest that a cocktail of antioxidants, endowed with different mechanisms of 
action, results more effectively than a single antioxidant because of the synergistic effect of the 
molecules. To promote possible synergistic mechanisms and to better understand the mechanistic 
aspects, the use of modified and/or dualistic molecules is a valuable approach.6 
Dehydroamino acids constitute an important class of non-proteinogenic amino acids with 
various biological activities, including antioxidant. N-phenolic and N-catecholic derivatives of 
dehydrophenylalanine were synthesized using a method which comprises coupling phenolic or 
catecholic acids and/or phenolic or catecholic amines. 
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Resumo 
O stress oxidativo é um desequilíbrio entre a quantidade de oxidantes e antioxidantes em favor 
dos oxidantes. Assim, quando há uma produção excessiva de espécies reativas de oxigénio (ROS) 
ou os mecanismos de defesa antioxidante estão diminuídos, ocorre stress oxidativo. Para manter 
o funcionamento celular normal, qualquer excesso de ROS deve ser continuamente inativado 
através da utilização de antioxidantes.1,2 
Aminoácidos fenólicos, como a tirosina, exibem uma ampla gama de atividades biológicas e 
mostraram-se antioxidantes eficazes em diferentes estudos de atividade antioxidante in vitro. Os 
ácidos fenólicos acoplados a aminoácidos estão envolvidos na supressão dos efeitos adversos do 
stresse oxidativo e possuem uma ampla gama de atividades biológicas, como antioxidante,3 
anticancerígeno4 e antimicrobiano.5 
Neste trabalho foi desenvolvida uma estratégia baseada na reação de Ugi para a síntese de 
novos aminoácidos fenólicos. Os derivados de hidroxibenzaldeido foram feitos reagir com 4-
metoxibenzilamina, isocianeto de ciclohexilo e ácido benzóico, ácidos fenólicos ou ácidos 
catecólicos para dar origem a aductos Ugi que foram tratados com ácido trifluoroacético originando 
amidas N-acil hidroxifenilglicina com bons rendimentos. A utilização de N-benziloxicarbonilglicina 
como componente ácido permitiu a preparação de um derivado dipeptídico de 3,4-di-
hidroxifenilglicil. Estudos de atividade de eliminação de radicais dos derivados de aminoácidos 
polifenólicos mostraram um aumento acentuado na atividade com o aumento do número de 
grupos hidroxilo ou catecol presentes. 
Vários estudos sugerem que, devido ao efeito sinérgico das moléculas, um cocktail de 
antioxidantes dotados de diferentes mecanismos de ação, resulta mais eficazmente do que um 
único antioxidante. Para promover possíveis mecanismos sinérgicos e compreender melhor os 
aspetos mecanísticos, o uso de moléculas modificadas e/ou dualísticas é uma abordagem valiosa.6 
Desidroaminoácidos constituem uma classe importante de aminoácidos não proteinogénicos 
com várias atividades biológicas, incluindo antioxidante. Derivados N-fenólicos e N-catecólicos da 
desidrofenilalanina foram sintetizados usando um método que compreende o acoplamento de 
ácidos fenólicos ou catecólicos e/ou aminas fenólicas ou catecólicas. 
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1.1. Oxidative stress and antioxidants 
1.1.1 Oxidative stress 
Oxidative stress is the term that refers to the imbalance between the formation of free radicals, 
namely, reactive oxygen (ROS) and nitrogen (RNS) species and the activity of the antioxidant 
defences.1 Free radicals are chemical species containing an unpaired electron. They are highly 
unstable, with extremely short half-life, very reactive and are constantly being formed in the human 
body.  
Most biological molecules are nonradicals that contain only paired electrons. Once radicals 
form, they can react either with another radical or with another molecule by various types of 
interactions. The rate and selectivity of these types of reactions depends on high concentrations of 
the radicals, on delocalization of the single electron of the radical (thus increasing its life time), and 
on the absence of weak bonds in any other molecules present with which the radical could interact.8 
Free-radical mechanisms have been implicated in the pathology of several human diseases. 
Oxidative stress, resulting from an exaggerated production of ROS/RNS or from reduction of 
mechanisms of antioxidant defences, has been implicated in the development of many 
neurodegenerative diseases (Figure 1) such as Parkinson and Alzhemier’s disease and is also 
responsible for aging, atherosclerosis, rheumatoid arthritis and carcinogenesis.9 Therefore, 
ROS/RNS production must be controlled in order to maintain normal cellular function. Any excess 
must be continuously inactivated by antioxidant enzymes or by using synthetic antioxidants.8 
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Figure 1 – Mechanisms of cellular damage in oxidative stress (adapted from reference 8). 
Antioxidant defences remove O2·− and H2O2. Superoxide dismutases (SOD) removes O2·− by 
greatly accelerating its conversion to H2O2. Catalases in peroxisomes convert H2O2 into water and 
O2 and help to dispose of H2O2 generated by the action of the oxidase enzymes that are located in 
these organelles. Other important H2O2-removing enzymes in human cells are the glutathione 
peroxidases.8 
When produced in excess, ROS can cause tissue injury. However, tissue injury can itself cause 
ROS generation, which may (or may not, depending on the situation) contribute to a worsening of 
the injury. Assessment of oxidative damage to biomolecules by means of emerging technologies 
based on products of oxidative damage to DNA (e.g., 8-hydroxydeoxyguanosine), lipids (e.g., 
isoprostanes) and proteins (altered amino acids) has advanced the understanding of the underlying 
mechanisms. This assessment also facilitates supplementation and intervention studies designed 
and conducted to test antioxidant efficacy in human health and disease.8 
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Oxidative stress can have natural causes or unnatural causes. Natural causes occur in situations 
of extreme physical exercise or in inflammatory processes. Unnatural causes result, for example, 
from the presence of xenobiotics in the body or from radioactive environments.10 
The chemical reactions that result from attack of ROS upon proteins are complex. Free-radical 
attack upon proteins generates radicals from amino acid residues, and electrons can be transferred 
between different amino acids (Figure 2). The levels of any one (or, preferably, of more than one) 
of these products in proteins could in principle be used to assess the balance between oxidative 
protein damage and the repair of (or, more likely, hydrolytic removal of) damaged proteins.8 
 
 
Figure 2 – Products of oxidative protein damage (adapted from reference 8). 
1.1.2. Antioxidants 
The free-radical reaction of lipid peroxidation, characterized as the oxidative deterioration of 
lipids containing any number of carbon-carbon double bonds, is an important issue in the food 
industry. Manufacturers minimize oxidation in lipid-containing foods by use of antioxidants during 
the manufacturing process; foods are produced that maintain their nutritional quality over a defined 
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shelf life. By contrast, biomedical scientists and clinicians are interested in antioxidants because 
they protect the body against damage by reactive oxygen species.8 
The body's exposure to free radicals from various sources has led the body to develop a number 
of defence mechanisms to eliminate these free radicals. Our antioxidant defence system includes 
endogenous antioxidants (enzymatic and non-enzymatic) and exogenous antioxidants, with the diet 
being the main source (Table 1). Endogenous and exogenous antioxidants act synergistically to 
maintain or re-establish redox homeostasis. An example is the regeneration of vitamin E by 
glutathione (GSH) or vitamin C to prevent lipid peroxidation processes, which can affect membrane 
fluidity and damage membrane proteins by e.g., inactivating receptors, enzymes and ion channels, 
even disrupting membrane integrity resulting eventually in cell death.11 
Table 1 – Human antioxidant defence systems.11 
Antioxidant defence system 
Endogenous antioxidants Exogenous antioxidants 
Enzymatic antioxidants: 
• Superoxide dismutase (SOD): enzyme 
detoxifying superoxide radical (O2·−) 
• Catalase (CAT) and glutathione peroxidase 
(GPx): enzymes involved in the detoxification of 
peroxides (CAT against H2O2, and GPx against 
both H2O2 and ROOH) 
• Glutathione reductase: enzyme involved in the 
regeneration of glutathione 
• Thioredoxin reductase: enzyme involved in the 
protection against protein oxidation 
• Glucose-6-phosphate dehydrogenase: enzyme 
involved in the regeneration of NADPH 
Principal dietary antioxidants from fruits, 
vegetables and grains 
• Vitamins: vitamin C, vitamin E 
• Trace elements: zinc, selenium 
• Carotenoids: b-carotene, lycopene, 
lutein, zeaxanthin 
• Phenolic acids: chlorogenic acids, gallic 
acid, cafeic acid, etc., 
• Flavonols: quercetin*, kaempferol*, 
myricetin* 
• Flavanols: proanthocyanidins and 
catechins 
• Anthocyanidins: cyanidin* and 
pelagonidin* 
• Isoflavones: genistein*, daidzein* and 
glycitein* 
• Flavanones: naringenin*, eriodictyol* 
and hesperetin* 
• Flavones: luteolin* and apigenin* 
Non-enzymatic antioxidants (principal intracellular 
reducing agents): 
GSH, uric acid, lipoic acid, NADPH, coenzyme Q, 
albumin, bilirubin 
*and their glucosides. 
 
The biological concept of antioxidant refers to any compound capable of inhibiting or retarding 
the oxidation of an oxidizable substrate. Antioxidants reduce oxidative stress and the associated 
diseases.8 
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Antioxidants that can directly neutralize ROS and terminate free radical mediated oxidative 
reactions have beneficial activities in protecting the human body from many chronic diseases. Also, 
antioxidants effectively retard the onset of lipid peroxidation by lowering the concentration of free 
radicals. However, an antioxidant that neutralizes free radicals usually becomes a radical species 
and can also be harmful.12 
Some antioxidants have toxicity and to prevent this, Bast and Haenen put forward a few points 
to follow when directly involved in natural product research and processing.13 These include: (1) an 
urgent change in the approach used to evaluate food additives and supplements to include arbitrary 
safety factors which allows extrapolation of research results from rat to human, (2) understanding 
of the bio-kinetics, bioavailability and biotransformation of food and drug ingredients should be 
extended, (3) biokinetic/bio-efficacy modelling should be used to help in standardizing dosages, 
and (4) the risk/benefit analyses of all supplements that have health claims should be warranted. 
High-dose antioxidant supplements do no good and obviously cause harm to human health while 
low dose mixtures can sometimes be good but may be recommended only for undernourished 
populations.14 
Because some synthetic antioxidants cause health risks, namely in the liver, and/or are related 
to carcinogenesis, the search for natural antioxidants has been greatly intensified in recent years. 
Among the various natural antioxidants, phenolic compounds are reported to be active, quenching 
oxygen derived free radicals by donating a hydrogen atom or an electron to the free radical.14 The 
catechol group normally imparts antiradical activity to molecules, being present in several 
antioxidants, as is the case of catecholamines and flavonoids. These antioxidants are capable of 
neutralizing reactive species.15 
1.2. Antioxidant amino acids 
1.2.1. Proteinogenic amino acids 
Natural phenols represent a wide class of compounds endowed with interesting biological 
activities. Phenolic compounds are widely studied as antioxidants because these compounds have 
a stable structure after the free radicals are quenched.9 Phenolic amino acids can be obtained from 
natural sources or synthetically.9 
An example of a natural phenolic amino acid is tyrosine. Studies have shown L-tyrosine to be 
an effective antioxidant in different in vitro antioxidant activity assays. 
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In a study on the antioxidant capacity (AOC) of amino acids and their derivatives, carried out by 
Torkova et al., experimental data on antioxidant properties were obtained in vitro.16 The peroxyl 
radical and the 2,2′-azino-bis-(3-ethyl-benzothiazoline-6-sulfonate) (ABTS) radical cation and are 
widely used in vitro to characterize natural antioxidants. The corresponding assays are known as 
oxygen radical absorbance capacity (ORAC) and trolox equivalent antioxidant capacity (TEAC), 
respectively. The authors concluded that in the ORAC assay, the AOC decreased in a row Trp > Tyr 
> Met = Cys > His. Only Cys, Tyr and Trp exhibited antioxidant activity in the TEAC assay in 
concentrations <1 mM, due to the lower reactivity of the ABTS cation-radical compared with the 
peroxyl radical. Thus, Tyr and Met demonstrated dissimilar tendencies in TEAC and ORAC assays: 
while Tyr exhibited the highest AOC against peroxyl radical and low AOC against ABTS, Met 
possessed no activity in the ORAC assay and was rather active against ABTS.16 
In order to study the influence of tyrosine C- and N-terminal modifications on its AOC, the 
authors investigated the antioxidant properties of tyrosine dipeptides with aliphatic amino acids. In 
the TEAC assay, the average AOC values for dipeptides with N- and C-terminal tyrosine were 4.81 
± 0.10 and 1.70 ± 0.27 µmol TE/µmol (micromoles of Trolox equivalents per micromole of 
sample), respectively. Dipeptides containing the N-terminal tyrosine residue exhibited, on average, 
1.4 times higher AOC values than free tyrosine (3.4 µmol TE/µmol) (Figure 3). Dipeptides with C-
terminal Tyr exhibit half the AOC values compared with free tyrosine. This testifies to the important 
role of a free tyrosine amine group, the presence of which, apparently, determines the mechanism 
of interaction of the tyrosine residues with cation-radical ABTS and the set of resulting products. In 
the ORAC assay, the AOC values of tyrosine dipeptides with aliphatic amino acids was practically 
no different from free tyrosine AOC.16 
 
 
Figure 3 – Antioxidant capacity of tyrosine dipeptides in TEAC assays (the red squares indicate 
peculiar behaviour of dipeptides with ionogenic side chains).16 
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The transmembrane domains of integral membrane proteins show an outstanding 
accumulation of tyrosine residues, especially in the region of highest lipid density, which comprises 
the inner portion of the lipid head groups and the beginning of the hydrocarbon tails. These residues 
perform vital antioxidant functions inside lipid bilayers and protect cells from oxidative destruction.14 
Long-chain acylated tyrosines are potent inhibitors of lipid peroxidation and oxidative cell death. 
The antioxidant functions of tyrosine may provide a specific explanation for their unique 
transmembrane distribution pattern and the high vulnerability of low-protein neuronal membranes 
to oxidative stress, as seen in neurodegenerative disorders.17 
According to Moosmann and Behl,17 the cytoprotective antioxidant effects of membrane-
anchored tyrosine may be explained by the special capability of the phenolic group to serve as 
hydrogen radical donor inside lipidic phases, thereby interfering with peroxidizing free radical chain 
reactions. Tyrosine residues themselves are converted to relatively stable and nonreactive phenoxyl 
radicals, a mechanism which has been used to rationalize the antioxidant effects of a wealth of 
nonpeptide low molecular mass antioxidants, among them estrogen, serotonin, and tocopherol. 
Chemically, phenoxyl radicals are much more stable and have longer lifetimes than simple peroxyl 
radicals, so any reverse reaction or the propagation of the radical-mediated peroxidizing chain 
reaction are inhibited. By being radicalized, tyrosine becomes more polar than their nonradicalized 
precursors, which may promote the preferred protrusion of these residues into zone 1 of the lipid 
bilayer, to come into contact with aqueous reducing molecules such as ascorbate or glutathione.17 
Low-protein membranes and artificially composed lipid-only membranes are much more 
vulnerable to oxidants and this is attributed to lack of membrane proteins and thereby of tyrosine; 
for instance, mitochondrial inner membranes with their high protein content are much more 
resistant to oxidative stress than myelin sheaths with their low protein content. This may explain 
the unique vulnerability of low membrane protein cell types in cases of oxidative degenerative 
diseases. 17 
In conclusion, the accumulation of tyrosine in transmembrane proteins protects the surrounding 
lipid bilayer from peroxidation. Thus, tyrosinyl lipids may constitute a novel class of 
pharmacologically useful cytoprotective antioxidants.17 
Tyrosine is also responsible for the formation of L-3,4-dihydroxyphenylalanine (L-Dopa). L-Dopa 
is the immediate precursor of the natural neurotransmitter dopamine and is widely used as 
medication in Parkinson’s disease, to alleviate the symptoms due to decreased dopamine levels in 
the brain. In addition, many studies show that L-Dopa antioxidant activity plays an important role 
1. Introduction 
9 
 
in the reduction of chronic diseases, mutagenesis and carcinogenesis by preventing H2O2-induced 
oxidative damage to cellular DNA.18 
The biosynthesis of L-Dopa from tyrosine starts by addition of a second hydroxyl group to the 
aromatic ring by the enzyme tyrosine hydroxylase. L-Tyrosine hydroxylation is the committed step 
in the synthesis of catecholamines and is subject to feedback inhibition by the end products. 
Subsequently, L-Dopa, can be decarboxylated by aromatic-L-amino acid decarboxylase to form 
dopamine.19 
Studies have shown L-Dopa to be an effective antioxidant in different in vitro antioxidant activity 
assays. Its activity is comparable to standard antioxidant compounds, such as butylated 
hydroxyanisole, butylated hydroxytoluene, -tocopherol and trolox, a water-soluble analogue of 
tocopherol. Also, L-Dopa demonstrated higher antioxidant and radical scavenging activities than L-
tyrosine. Thus, the antioxidant activities seem to be highly controlled by the number of phenolic 
hydroxyl groups.12 
 
1.2.2. Non-proteinogenic amino acids 
Non-coded amino acids can have a variety of applications such as antiviral, antitumor, anti-
inflammatory or immunosuppressor compounds, in structure-activity relationship studies or in the 
development of new biomaterials.20-22 On several occasions unnatural -amino acids have been 
used to modify the conformation and/or stability of a biologically active peptides. The 
pharmacological properties of a peptide are a function of its conformation, which in-turn is dictated 
by the amino acid composition and sequence. In this respect, unusual amino acids are useful for 
carrying out more systematic studies (e.g., QSAR). For example, incorporation of -aminoisobutyric 
acid into oligopeptides is known to rigidify the peptide backbone through the formation of β-turns 
or -helices.21 Therefore, incorporation of these amino acids into peptides and proteins is a good 
way to obtain compounds with new chemical, structural and pharmacological properties. 
1.2.2.1. Phenolic amino acids 
1.2.2.1.1. Hydroxyphenylglycine 
The non-proteinogenic amino acid p-(hydroxyphenyl)glycine is found in several peptidic natural 
products including the vancomycin group of antibiotics (e.g. vancomycin, chloroeremomycin, 
A47934 and complestatin) as well as other antimicrobial compounds such as ramoplanin. The p-
(hydroxyphenyl)glycine residues play crucial roles in the structure and function of these antibiotics 
and of the final glycopeptide antibiotic. In vancomycin and chloroeremomycin, the D-p-
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(hydroxyphenyl)glycine residue at position four of the heptapeptide is oxidatively cross-linked with 
the aryl rings of halogenated β-hydroxytyrosines at positions two and six, creating part of the rigid 
scaffold characteristic of these antibiotics (Figure 4).23 
 
Figure 4 – Chemical structures of representative p-(hydroxyphenyl)glycine (highlighted in red) 
containing peptidic natural products.23 
The committed synthesis of p-(hydroxyphenyl)glycine and the clustering of the enzymes for its 
proposed biosynthetic pathway with other enzymes for vancomycin assembly, suggests this residue 
provides reactivity and/or architecture not available with the proteinogenic homolog tyrosine.19 
Proposals for p-(hydroxyphenyl)glycine biosynthesis for vancomycin group antibiotics have been 
based on labelling studies where either [13C]tyrosine or [2H,13C]tyrosine was fed to growing cultures. 
Analysis of the final glycopeptide product showed incorporation of the labelled residues as D-p-
(hydroxyphenyl)glycine residues, leading to the conclusion that these are derived from tyrosine.24 
The strongest in vivo support for this proposed p-(hydroxyphenyl)glycine biosynthetic pathways 
comes from [14C]tyrosine incorporation into the antibiotic nocardicin A (Figure 5). In this L-lactam 
antibiotic, two molecules of p-(hydroxyphenyl)glycine are incorporated into the final product.23 
 
Figure 5 – Structure of nocardicin A. 
Vancomycin Chloroeremomycin 
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1.2.2.1.2. Di(hydroxyphenyl)glycine  
Catechols are benzene derivatives with two neighbouring (ortho-) hydroxyl groups that occur 
ubiquitously in nature. For example, catecholamine neurotransmitters, such as adrenaline and 
noradrenaline, fulfil essential and well-defined biochemical roles. Catechol derivatives can also be 
found as active species in a variety of environments, displaying a remarkable degree of chemical 
and physico-chemical versatility that has already inspired, and is still leading to, an ever-growing 
number of applications as functional materials.25 
Despite the diverse properties of cathecolic compounds, little attention has been given to amino 
acids with the ortho-dihydroxyaryl function, such as 3,4-dihydroxyphenylglycine (DOPG). The 
chemical synthesis of 3,4-dihydroxyphenylglycine has been accomplished by Strecker's synthesis 
and demethylation reactions using as starting material 3,4-dimethoxybenzaldehyde and its 
enzymatic oxidation by tyrosinase studied.26 Tyrosinase is a copper-containing enzyme widely 
distributed in nature. It catalyses the hydroxylation of monophenols to ortho-diphenols and the 
oxidation of the latter to ortho-quinones using molecular oxygen.27 
Synthetic 3,4-dihydroxyphenylglycine was used as a substrate for mushroom tyrosinase.26 UV 
and visible spectral studies during the enzymatic oxidation of 3,4-dihydroxyphenylglycine showed 
that tyrosinase readily oxidized DOPG to the expected quinone. The glycyl-o-benzoquinone thus 
formed was highly unstable like its higher analogue, dopaquinone. However, unlike its counterpart, 
it failed to exhibit intramolecular cyclization reactions. Rather, glycyl-o-benzoquinone exhibited facile 
transformation to ultimately generate 3,4-dihydroxybenzaldehyde. Thus, it is assumed that 3,4-
dihydroxyphenylglycine cannot undergo intramolecular Michael 1,4-addition like dopaquinone, due 
to the unfavourable positioning of the amino group. 
Gąsowska et al. conducted a similar study with amino-(3,4-dihydroxyphenyl)methyl phosphonic 
acid, the phosphonic analogue of 3,4-dihydroxyphenylglycine, which is a potent inhibitor of 
tyrosinase. This compound turned out to be a substrate and was oxidized to o-quinone, which 
evolved to a final product identified as 3,4-dihydroxybenzaldehyde, the same as for 3,4-
di(hydroxyphenyl)glycine.27 
3,4-Dihydroxyphenylglycine has also been studied as copper ligand. Stereochemical 
considerations are thought to have a large bearing on the identity and strength of the complexes 
and complex polymers formed when these species involve simultaneous chelation of both sites of 
the ligand to metal ions. Such effects are very apparent in comparisons of the polymerization 
schemes of 3,4-dihydroxyphenylglycine (DOPG) and L-β-(3,4-dihydroxyphenyl)alanine (DOPA). The 
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two ligands are very similar, but DOPG has a side chain shorter by one -CH2- group, and is, 
therefore, a less flexible molecule which leads to markedly different polymerization reactions. Thus, 
when the polymerization of the DOPA-copper system was compared to that of DOPG, closed ring 
dimerization does not occur, a difference attributable to the lower flexibility of the side-chain of this 
catecholamine.28 
Based on the results obtained titrations at 1:1 molar ratio of DOPG to copper showed the 
formation of the 1:1 amino acid-copper type complex.24 The authors thus proposed the formation 
of a DOPG-Cu(II) tetramer (Figure 6). 
 
Figure 6 – Probable DOPG-Cu(II) tetramer.28 
1.2.2. Dehydroamino acids 
α,β-Dehydroamino acids (Δaa) are non-proteinogenic amino acids that contain a double bond 
between the α carbon and the β carbon (Figure 7). Dehydroamino acids constitute an important 
class of non-proteinogenic amino acids with various biological activities.2,7,8,29-38 They are key 
intermediates in the synthesis of new amino acids and peptides, being found in several natural 
antibiotics and also play an important role in the active centre of some enzymes.39 
The most common α,β-dehydroamino acids are dehydroalanine (ΔAla), dehydroaminobutyric 
acid (ΔAbu), dehydrophenylalanine (ΔPhe), dehydrovaline (ΔVal) and dehydroleucine (ΔLeu) 
(Figure 7).40 
 
Figure 7 – Structure of the most common α,β-dehydroamino acids. 
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Due to the existence of the double bond that gives them a planar geometry and allows the 
existence of E/Z isomerism, dehydroamino acids have properties different from their saturated 
equivalents. Dehydroamino acids are not free in nature because they are very unstable and can 
undergo hydrolysis. They appear in some bacteria, yeasts and natural antibiotics.40 
Dehydroamino acids activities include antioxidant properties, functioning as radical scavengers 
since they form stabilized free radical adducts, react with, and scavenge oxygen and hydroxyl 
radicals.8 In a study realized by Suzen et al., eleven N-acetyl dehydroalanine derivatives (N-acetyl 
DHA) were synthesised to evaluate their antioxidant properties on rat liver lipid peroxidation (LP) 
levels and 2,2-diphenyl-1-picryl hydrazyl (DPPH) free radical scavenging activity.9 In order to identify 
the possible structure - antioxidant activity relationships and to guide in the design of new 
analogues, several dehydroalanine derivatives in the form of amides with aliphatic or cyclic chains 
were studied (Figure 8). Compounds c, f and j slightly scavenged the level of DPPH radical by about 
27, 46, and 56%, respectively. However, compounds a, d, e, f, g and h showed a strong inhibitory 
effect on LP and the inhibition was in the range 76–90%. Compounds b, c and i also inhibited LP 
by about 54%, 58% and 66%, respectively but compounds j and k had no inhibitory LP activity at 
the same concentrations. The authors concluded that N-acetyl DHA derivatives which are 
substituted with aliphatic (up to 3 or 4 carbons) and cyclic side chains (5 membered) have 
significant hydroxyl radical scavenging activity.9 
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Figure 8 - N-Acetyl dehydroalanine derivatives (adapted from reference 9). 
Continuing their study on the antioxidant activity of dehydroalanine, Suzen et al. studied various 
N-substituted dehydroalanine derivatives (Figure 9) using DPPH and superoxide (O2.-) radical 
scavenging activity assays, and the in vitro effects on rat liver lipid peroxidation levels.2 The results 
obtained where compared to α-tocopherol as reference. α-Tocopherol is a powerful antioxidant that 
is beneficial in the treatment of many free radical related diseases.9 
No significant results were obtained with the DPPH and superoxide radical scavenging activity 
assays. However, all the compounds were effective in the LP experiment, allowing the conclusion 
that these dehydroalanine derivatives are able to scavenge OH. radical, rather than DPPH or 
superoxide radicals. These result were similar to the earlier findings, in which the N-acetyl 
dehydroalanine derivatives showed a strong inhibitory effect on lipid peroxidation, while they had 
very little or no effect on DPPH radical.9 
These studies led the authors to conclude that dehydroalanine derivatives, which are reactive 
Michael acceptors, can be active in vitro against oxidants. 
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Figure 9 – Methyl esters of N-substituted dehydroalanine (adapted from reference 2). 
1.3. Phenolic acids coupled with amino acids 
Several studies suggest that a cocktail of antioxidants, endowed with different molecular 
structures and mechanisms of action, result more effective than a single antioxidant, due to the 
synergic effect between different types of molecules.6,41-45 
Silvia et al. proposed the synthesis of a new set of molecular combinations of phenolic acid-
amino acid and of phenolic acid-amino acid-dopamine conjugates.46 The aim was to investigate the 
influence of the different phenolic moieties (in particular caffeic acid and 3,4-dihydroxyphenylacetic 
acid) on the antioxidant activity of the resulting molecules and thus improve the antioxidant activity 
of natural amino acids. It was shown that for significant antioxidant activity at least two hydroxyl 
moieties on the aromatic ring are necessary, as well as a spacer between the aromatic ring and 
the carboxylic acid. The trimer compounds phenolic acid-amino acid-dopamine, showed no 
significant improvement of the antioxidant activity due to the presence of the two additional OH 
groups from the dopamine moiety. This latter finding suggests that also the shape and complexity 
of the molecule may play a role and that there is a “saturation” on the maximum potency 
achievable by this approach.46 The results obtained confirm that, molecular combinations improve 
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the antioxidant efficiency of natural antioxidants, this effect being designated by the author as the 
Centaurus tactic. 
1.3.1. Phenolic acids coupled with proteinogenic amino acids 
Phenolic acids coupled with amino acids or amines can be obtained from natural sources such 
as, fruits, vegetables and beverages or synthetically. It is assumed that these bioactive substances 
are involved in suppression of deleterious effects of oxidative stress and have a wide range of 
biological activities such as antioxidant,3,47-50 anticancer4 and antimicrobial.5, 51-55 In fact, the 
accumulation of hydroxycinnamic acid amides constitutes part of the defence system of plants that 
is activated as a response to various environmental stimuli such as wounding, fungal infection or 
heavy metal ions.56-59 
To find more active antioxidants with the hydroxycinnamoyl moiety, Wei Q-Y et al.3 synthesized 
a series of N-hydroxycinnamoyl amino acid esters and evaluated their antioxidative activities by 2,2-
diphenyl-1-picryl hydrazyl (DPPH) radical scavenging and human red blood cells haemolysis 
methods. It was found that: 
-  N-caffeoyl amides exhibited the highest DPPH scavenging activities, whereas N-feruloyl amides 
demonstrated the highest antihaemolysis activities among the three different 
hydroxycinnamamides studied (caffeoyl, feruloyl, and p-coumaroyl); 
- hydroxycinnamoyl amides were more effective than their corresponding free acid and ester 
compounds.  
Thus, they concluded that the synthetic amide analogues of hydroxycinnamic acids exhibit 
stronger antioxidative activity than their corresponding free acids and esters. 
This stronger antioxidative activity of linked phenolic compounds could be indirectly found in a 
study by Brand-Williams et al. These authors found a low antioxidant efficiency of the 
monohydroxylated compounds namely, phenol, coumaric acid, vanillin and vanillic acid. This may 
be explained by the presence of an electron withdrawing group (CHO or COOH) or, as is the case 
of phenol, the absence of any electron donating group. This poor aromatic ring resonance of the 
phenoxyl radical considerably lowers the antiradical efficiency.60 
The observation that amides bearing ortho-methoxyl group vicinal to the hydroxyl functionality 
exhibit markedly higher antihaemolytic activities gave useful information for antioxidant drug 
design.61  
Lee et al. prepared N-(4-hydroxycinnamoyl)-L-phenylalanine methyl ester (compound 1, Figure 
10), N-(3,4-dihydroxyhydrocinnamoyl)-L-aspartic acid dibenzyl ester (compound 2, Figure 10), and 
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N-(3,4-dihydroxyhydrocinnamoyl)-L-alanine methyl ester (compound 3, Figure 10) and evaluated 
their biological activities on lipoprotein metabolism.61 
 
 
 
 
 
1 
 
 
 
 
2 
 
 
 
 
3 
Figure 10 – Structure of N-(hydroxycinnamoyl) amino acid derivatives (adapted from reference 
61). 
These authors found that compounds 1 and 2 inhibited human acyl-CoA:cholesterol 
acyltransferase (ACAT) activities. Compounds 1 and 2 also served as antioxidants against copper 
mediated low-density lipoprotein (LDL) oxidation. Compound 3 showed a potent in vivo activity, 
with significant reduction of atherosclerotic lesion formation in hypercholesterolemic rabbit without 
improvement of serum lipid profile. These results suggest that the new cinnamic acid derivatives 
possess useful biological activity as anti-atherosclerotic agents.61 
Another application of phenolic or catecholic amino acids is in the design of new peptide 
hydrogels that mimic mussel adhesive proteins. The extraordinary ability of mussel adhesive 
proteins is mainly attributed to the reversible metal-catechol coordination between metals like Fe3+ 
and catechol groups from the amino acid 3,4-dihydroxyphenyl-L-alanine (DOPA), and also to other 
interactions such as cation-p interactions.62 
Mussel adhesion protein–inspired polymer research is motivated by the idea that the 
exceptional adhesive properties exhibited by the native proteins can be captured in synthetic 
polymer systems. A variety of chemical approaches may be employed, giving rise to linear or 
branched polymers functionalized with Dopa, Dopa peptides, or their catechol mimetics. These 
polymers provide simple platforms for studying the role of Dopa in mussel adhesion, as well as 
novel materials for wet adhesion. One of the compelling uses for these materials is in medical 
adhesion and sealing, in which catechols enhance adhesion to wet tissue surfaces. Progress is 
being made towards the development of mussel mimetic polymers capable of repairing both soft 
and hard tissues. Finally, there is rapid adoption of mussel mimetic polymers in the coatings field. 
Here, the adhesive qualities of the catechol may be important for anchoring polymers, 
biomolecules, and other compounds onto solid surfaces. With careful design of polymer 
composition and architecture, these coatings can give rise to adhesive or antiadhesive coatings.63 
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1.3.2. Phenolic acids coupled with dehydroamino acids 
Due to the antioxidant properties of dehydroamino acids, their combination with phenolic or 
catecholic moieties can be a valuable approach for the development of new biologically active 
compounds. 
In order to explore the previously proposed “Centaurus tactic”, Monteiro et al.64 combined the 
dehydroamino acid moiety with phenolic or catecholic acids. Thus, an innovative strategy for the 
synthesis of a series of N-phenolic and N-catecholic dehdroalanine and dehydrophenylalanine 
derivatives was developed. This methodology was applied with N-phenolic or N-catecholic serine or 
phenylserine methyl esters to give the corresponding dehydroalanine or dehydrophenylalanine 
derivatives (Figure 11). 
 
Figure 11 – Methyl esters of N-phenoyl and N-catechoyl dehydroalanine and dehydrophenylalanine 
(adapted from reference 64). 
The toxicity of these dehydroalanine and dehydrophenylalanine derivatives was evaluated 
against a panel of human cancer and non-cancer cell lines. Preliminary assays on the toxicity on 
gastric cancer (AGS) and lung cancer (A549) cell lines, showed that the most potent molecules 
were the dehydrophenylalanine derivatives, which can be attributed to their higher liposolubility. 
Assays of these compounds on cell viability against a non-cancer cell line [lung fibroblasts (MRC-
5)], showed that the molecules display very low or no toxicity. Thus, the toxicity of the molecules 
was higher towards cancer cells than non-cancer cells.64 
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1.4. Synthetic methodologies 
1.4.1. Multicomponent reactions  
In chemical reactions, usually only one or two chemical compounds participate. If more than 
two adducts are converted into products, usually such synthesis requires sequences of chemical 
reactions. Typically, after each step the intermediate or final product must be isolated and purified. 
The more steps needed, the more preparative work must be accomplished and with each step the 
yield of the final product decreases.  
One-pot reactions that form products from three or more starting compounds are called 
multicomponent reactions (MCR).65 The reagents may be different individual molecules, or they 
may be different functional groups present in the same reagent.  
MCRs may be older than life. It is assumed, that adenine, one of the nitrogenous bases of DNA 
and RNA, prebiotically originates from five molecules of hydrogen cyanide. Note that each one of 
those five molecules plays a different role.  
MCRs allow a great variety of products to be formed in a higher yield than by conventional 
multistep synthesis. Usually the starting materials are readily available or can easily be prepared.66 
The first important MCR was discovered in 1850 by Strecker.67 It is a three-component 
condensation of ammonia, an aldehyde, and hydrogen cyanide, leading to -cyano amines, which 
can easily be hydrolysed to -amino acids. In 1890, Hantsch discovered that -chloro oxo 
compounds, ammonia, and 1,3-dioxo compounds condense to form pyrrol.68 Bignelli introduced a 
three component dihydropyrimidine synthesis in 1893.69 The best known MCR is Mannich's three 
component condensation (M-3CC) in which an amine and formaldehyde combine to form a Schiff 
base (imine) which subsequently reacts with an -acidic reagent.70 In 1921, Passerini described 
one of the most important reactions of isocyanides, a three-component condensation (P-3CC), in 
which they are reacted with a carboxylic acid and an oxo compound.71 Bucherer and Bergs were 
the first to describe a MCR of four compounds (BB-4CC) in 1933.72 Hydroformylation, is a very 
important MCR, described in 1948 by Roelen.73 Asinger found a general thiazolidine synthesis in 
1958. Two equivalents of an aldehyde or ketone react with sulphur and ammonia (A-3CC), and, 
alternatively, an -halo oxo compound, ammonia, an oxo compound, and sodium hydrogen 
sulphide react to form a thiazolidine (A-4CC).74 In 1959, Ivar Ugi investigated an efficient procedure, 
which allows the simultaneous joining of 4 different fragments: an isocyanide, an aldehyde, an 
amine and a carboxyl acid giving rise to α-acetamido carboxamides. (U-4CC).75 The last important 
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MCR is the Pausen-Khand reaction, published in 1971, where substituted cyclopentenones are 
easily accessible by this three-component reaction involving carbon monoxide, an alkyne, and an 
alkene.76 
Multicomponent reactions have emerged in the last 20 years as a powerful tool in drug 
discovery. They are intrinsically endowed with high economic advantages and operational 
simplicity, being perfectly suited for rapid generation of libraries resulting from the high diversity of 
inputs.77 
1.4.1.1. Ugi reaction 
One important multicomponent reaction is the Ugi reaction (U-4CC), first reported by Ivar Ugi, 
in 1959 in which the condensation of an aldehyde, an amine, a carboxylic acid and an isocyanide 
occurs in a one-pot procedure. The Ugi reaction has allowed the preparation of molecules with high 
diversity. It is a valuable tool for generating α-amino acid derivatives in a very straightforward 
manner.  
Two possible mechanisms for the Ugi reaction have been postulated (Scheme 1). In both 
mechanisms, the first step involves condensation of aldehyde 1 and amine 2 to give an imine that 
is protonated by the carboxylic acid 3. The debate is whether the next step involves introduction of 
the carboxylic acid to 10, causing isocyanide 4 to react with 11 via a SN2 mechanism, or whether 
the isocyanide 4 first undergoes nucleophilic addition to imine 6, followed by the addition of 
carboxylate 8 to 7.  Experiments supporting the formation of intermediate 7 versus 11 have not 
been performed.78 
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Scheme 1 – Postulated mechanism of the U-4CC (adapted from reference 78). 
A strategy based on the modified Ugi reaction using as amine component 4-
methoxybenzylamine and several isocyanide derivatives, followed by treatment of the adducts with 
trifluoroacetic acid (TFA) has been explored 79 This method enabled the synthesis of several N-
acetylamino acids derivatives (compounds 4a-d, Scheme 2). Schiff bases were prepared by 
azeotropic reflux of 4-methoxybenzylamine and diethyl, dipropyl, diisobutyl or dibenzyl ketone in 
toluene. The required isonitriles were prepared from the corresponding formamides. The Schiff 
bases were combined with the isonitriles and acetic acid in dry methanol and allowed to react at 
room temperature for one to two weeks. The expected Ugi–Passerini adducts, were obtained, 
usually in high yields independently of the bulkiness of the reagents or that of the reaction products. 
The Ugi–Passerini adducts were reacted with neat trifluoroacetic acid under reflux to remove the 
4-methoxylbenzyl group at the amine function. The hydrolysis of the N-acetylamino acids with 
hydrochloric acid gave the corresponding free derivatives or their hydrochlorides in excellent yields 
(Scheme 2). 
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Scheme 2 – Synthesis of ,-dialkylglycines by the Ugi–Passerini reaction (adapted from reference 
79). 
The authors demonstrated that neither the bulkiness of the dialkyl glycine side chains nor the 
nature of the isonitrile moiety seems to affect the lability of the amide bond at the C-terminus, thus 
allowing good cleavage selectivity and yields in all cases. Thus, the choice of the isonitrile should 
be based only on the availability and price of the starting material. In addition, the use of 4-
methoxybenzylamine seems to be a good choice to allow the easy removal of the N-alkyl group 
present in the Ugi–Passerini adduct. Their results suggest that this is the best route for the 
synthesis of bulky α,α-dialkylglycines, as it involves simple procedures in clean reactions, leading 
to high overall yields, usually above 60%.79 This procedure using as aldehyde component phenolic 
or catecholic benzyladehydes and as acid component phenolic or catecholic acids, could be an 
efficient approach for the synthesis of novel N-phenoyl or N-catechoyl (hydroxyphenyl)glycines. 
1.4.1.2. Synthesis of polyphenolic amino acids by Ugi reaction 
A simple approach to obtain conjugates of phenolic acids with (hydroxyphenyl)glycines would 
be a strategy where simple natural phenols are joined together in a one-step economical way. If 
hydroxyl-substituted benzoic acid, benzaldehyde, aniline, or isocyanides are employed in the Ugi 
reaction, the bis-amide obtained may be a suitable substrate for exploring the mutual antioxidant 
effects among phenolic hydroxyl groups at different positions. Reports on the application of Ugi 
reaction to construct antioxidants are not usually found, and the influence of the isocyanide moiety 
on antioxidant effectiveness remains unclear.80 Wang and Liu investigated the mutual antioxidant 
effects of hydroxyl groups attached to different benzaldehyde and carboxylic acid components, as 
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well as the influence of the isocyanide component, on the antioxidant effect of bis-amides obtained 
by Ugi condensation. Some of the evaluated compounds are present in Table 2. 
Table 2 – Structure of bis-amides obtained by Ugi condensation (adapted from reference 80). 
 
Comp. R1 R2 R3 R4 R5 R6 
1 H H H H 
 
-CH2COOC2H5 
2 H H H H 
 
-CH2COOC2H5 
3 H H H H 
 
-CH2COOC2H5 
4 H H H H 
 
-C(CH3)3 
5 H H H H 
 
 
For quenching DPPH and galvinoxyl radical, the rate constant (k) values of compounds 3, 4 and 
5 are higher than those of other equivalent compounds (1 and 2). This shows that the 1,2,3-
trihydroxyl groups attached to phenyl group A is the major functional group contributing to radical 
scavenging activity. Furthermore, by the comparison of k values of compounds 3, 4 and 5, it is 
found that the ferrocenylmethyl group enhances the k value of compound 5 markedly. However, 
in a comparison of abilities of these compounds to reduce the radical (quenching ABTS•+), the 
ferrocenylmethyl group enhances the k value of compound 5 not very significantly. The increasing 
effect of the isocyanide moiety on the antioxidant property follows the sequence ferrocenylmethyl 
group > tert-butyl group > ethoxycarbonyl group. Hence, the hydrogen atom donating ability is 
mainly due to the hydroxyl group attached to phenyl group A, which may be reinforced by the 
ferrocenylmethyl group.80 
The authors concluded that the Ugi four-component reaction provides a powerful tool for 
integrating phenolic hydroxyl groups within a bis-amide molecule, giving substrates suitable for 
1. Introduction 
24 
 
exploring the mutual antioxidant effects among phenolic hydroxyl groups attached to different parts 
of the molecule.80 It is actually found that the antioxidant property of the phenolic hydroxyl group at 
one tip of the molecule depends upon the isocyanide moiety at another tip of the molecule, in 
which ferrocenylmethyl isocyanide enhances the antioxidant effect markedly. Thus, the isocyanide 
moiety influences the antioxidant effect of the hydroxyl group at a long distance within a molecule. 
Mutual antioxidant effectiveness is also found among phenolic hydroxyl groups at the side chain.  
Despite the wide range of combinations of hydroxyl bis-amides prepared by Wang and Liu, no 
derivatives with the ortho-catechol moiety as the amino acid side chain were report. 
1.4.2. Synthesis of dehydroamino acids 
Dehydroamino acids are not found free in nature, but have been synthesized as derivatives of 
amines, carboxylic esters or N-acylated derivatives.  
The most important methods of synthesis of α,β-dehydroamino acids are those related to the 
biosynthetic pathway, that is by elimination reactions. There are several possible routes, such as: 
the dehydration of N-hydroxyamino acids; the dehydration of -hydroxyamino acids; the direct 
oxidation of amino acids; or elimination reactions in β-hydroxy or β-mercapto amino acids.81,82 
The simplest method for the synthesis of dehydroamino acids is by β-elimination reactions using 
as precursors β-hydroxyamino acids, such as serine and threonine, to give the corresponding 
dehydroamino acid, dehydroalanine (ΔAla) and dehydroaminobutyric acid (ΔAbu), respectively.81,82 
Various dehydration reagents have been used to carry out the β-elimination reactions.83-87 
Ferreira et al., developed an efficient method for the synthesis of N,N-diacyl-α,β-dehydroamino 
acid derivatives by using two equivalents of tert-butyldicarbonate (Boc2O) and 4-
dimethylaminopyridine (DMAP) as catalyst in dry acetonitrile. They found that formation of the tert-
butyl carbonate derivative of the -hydroxyamino acid occurred, followed by introduction of a Boc 
group as a second acylating group. The tert-butyl carbonate group is eliminated with formation of 
the corresponding dehydroamino acid derivative in excellent yield. This reaction is stereoselective, 
yielding the Z-isomers of dehydroaminobutyric acid and dehydrophenylalanine derivatives (Scheme 
3).88,89 
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Scheme 3 - Synthesis of N,N-diacydehydroamino acids derivatives (adapted from references 88, 
89). 
This method was also applied in the preparation of dehydrodipeptides by reacting dipeptides 
containing serine, threonine or β-hydroxyphenylserine with three equivalents of tert-
butyldicarbonate to give dehydrodipeptides in high yields (74-96%).  
In order to allow the synthesis of N-monoprotected dehydroamino acid derivatives, a 
modification of this method was subsequently reported.90 Thus, by reacting β-hydroxyamino acid 
derivatives with one equivalent of Boc2O and DMAP it was possible to obtain the corresponding β-
carbonates that undergo β-elimination by treatment with N,N,N’,N’-tetramethylguanidine (TMG)  
(Scheme 4). 
 
Scheme 4 – Synthesis of N-acyldehydroamino acids derivatives (adaptaded from reference 90). 
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1.4.2.1. Synthesis of phenolic acids coupled with dehydroamino acids 
Monteiro et al.64 developed an innovative strategy for the synthesis of the methyl esters of N-
phenoyl and N-catechoyl dehydroalanine and dehydrophenylalanines. N-Protected β-hydroxyamino 
acid derivatives were treated sequentially in a one-pot procedure by reaction with tert-
butyldicarbonate and dimethylaminopyridine, followed by treatment with N,N,N’,N’-
tetramethylguanidine and cleavage of the aromatic O-tert-butyloxycarbonyl groups with 
trifluoroacetic acid to give methyl esters of N-phenolic or N-catecholic dehydroalanine or 
dehydrophenylalanine (Scheme 5, compounds 3a, 3c, 3e, 3f and 4a-4g). 
 
Scheme 5 – Synthesis of the methyl esters of N-phenoyl and N-catechoyl dehydroalanine and 
dehydrophenylalanine (adapted from reference 64). 
Due to the high hydrophilic character of compounds 1b, 1d and 1g when compared with the 
other serine derivatives (compounds 1a, 1c, 1e and 1f) the former could not be isolated. The lower 
hidrophylicity of the phenylserine derivatives obtained allowed the preparation of all N-protected 
phenylserine derivatives in good yields (compounds 2a-2g).  
Due to the relative ease with which catechol groups oxidize, are prone to nucleophilic attack 
and phenolic coupling reactions in basic media, it is not possible to remove the methyl esters from 
compounds such as 3f or 4f. Alternatively, the C-deprotected N-catechoyl dehydroamino acid 
derivatives were prepared by a sequential tert-butyloxycarbonylation and dehydration; followed by 
treatment with base to remove the methyl ester and cleavage of the Boc groups with TFA.  
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Scheme 6 - Two-step procedure to prepare C-deprotected N-protocatechoyl dehydrophenylalanine 
(adapted from reference 64). 
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2.1. Synthesis of phenolic and catecholic amino acid derivatives by the modified 
multicomponent Ugi reaction 
To obtain new phenolic and catecholic amino acids, a strategy based on modified Ugi 
multicomponent reaction was employed. Multicomponent reactions (MCR) are one-pot reactions 
that form products from three or more different starting compounds.65 The reagents may be 
different individuals molecules or they may be different functional groups in the same reagent. 
The Ugi reaction is the condensation of an aldehyde, an amine, a carboxylic acid and an 
isocyanide in one-step.91 This reaction has enabled the preparation of molecules with high diversity 
and is a valuable tool for generating α-amino acid derivatives. The combination of various carboxylic 
acids, aldehydes, amines or isocyanides gives hundreds of bis-amides with different biological 
activities. The Ugi four-component reaction has allowed the integration of phenolic hydroxyl groups 
within a bis-amide molecule, giving substrates suitable for exploring the antioxidant effects of 
different phenolic components.80 
The procedure proposed uses as amine component 4-methoxybenzylamine and as isocyanide 
fragment cyclohexyl isocyanide. The carboxylic acid component used initially was benzoic acid and 
the aldehyde component bared the phenolic or catechol moiety (Scheme 7). The Ugi adduct formed 
would be subsequently treated with trifluoroacetic acid (TFA) to remove the methoxybenzylamine 
group and eventually also the cyclohexylamine. 
 
Scheme 7 – Synthesis of phenolic and catecholic amino acid derivatives by the modified 
multicomponent Ugi reaction. 
 
2.1.1. Synthesis of O-tert-butyloxycarbonylated benzaldehydes 
Use of phenolic or catecholic aldehyde components in the Ugi reaction requires previous 
protection of the hydroxyl functions. This need arises from the limitations of the use of ortho-
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catechol moiety in synthesis due to its high instability in basic environment. This basic environment, 
in this case, arises from the nature of the amine component. 
The choice of hydroxyl protection was as tert-butyl carbonates, which has been recently applied 
in the synthesis of phenolic and catecholic dehydroamino acid derivatives.  The advantage of this 
type of protection is that O-tert-butyloxycarbonylated benzaldehydes can be easily obtained by 
reaction of hydroxybenzaldehydes with tert-butyldicarbonate in the presence of 
dimethylaminopyridine (DMAP) as catalyst.64 Furthermore, this temporary protection can be 
removed in the subsequent treatment with TFA. 
In order to test the O-tert-butyloxycarbonylation of hydroxybenzaldehydes, the simpler aldehyde, 
4-hydroxybenzaldehyde, was used. To this benzaldehyde, one equivalent of tert-butyldicarbonate 
(Boc2O) was added followed by 0.1 equivalents of dimethylaminopyridine (DMAP) in dry acetonitrile 
(Scheme 8). After reacting for 4h, treatment of the reaction mixture gave tert-butyl (4-formylphenyl) 
carbonate (compound a, Scheme 8)92 in 96% yield. 
 
Scheme 8 – Synthesis of tert-butyl (4-formylphenyl) carbonate. 
The high yield obtained in this reaction, allowed us to proceed with the protection of different 
aldehydes. Thus, three more benzaldehydes bearing hydroxyl functions, namely, 3-methoxy-4-
hydroxybenzaldehyde, 3,4-dihydroxybenzaldehyde and 2,3-dihydroxybenzaldehyde were reacted 
with tert-butylpyrocarbonate in the presence of dimethylaminopyridine to give O-(tert-
butyloxycarbonyl) benzaldehydes (Scheme 9, compounds b93, c94 and d). All compounds including 
the highly sterically hindered di-tert-butyl (3-formyl-1,2-phenylene) dicarbonate, compound d, could 
be obtained in excellent yields (Table 3). 
 
Scheme 9 – Synthesis of O-(tert-butyloxycarbonyl) benzaldehydes. 
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Table 3 – Yields and characteristics of O-(tert-butyloxycarbonyl) benzaldehydes. 
Compound IUPAC Name Yield Characteristics 
a tert-Butyl (4-formylphenyl) carbonate 96% white solid 
b  tert-Butyl (4-formyl-2-methoxyphenyl) carbonate 95% white solid 
c  di-tert-Butyl (4-formyl-1,2-phenylene) dicarbonate 94% light brown oil 
d di-tert-Butyl (3-formyl-1,2-phenylene) dicarbonate 96% light brown solid 
 
2.1.2 Synthesis of Ugi adducts 
The Ugi reaction is usually carried out in two steps. Initially an imine is obtained by condensation 
of an amine with an aldehyde to give the corresponding Schiff base (Scheme 10). Subsequently, 
the carboxylic acid and the isocyanide components are added to give the classical Ugi skeleton. 
Carrying out the reaction in these two steps has proved to increase the overall yield in Ugi adduct. 
 
Scheme 10 – The Ugi reaction in two steps (adapted from reference 91). 
A preliminary test was carried out using as reactants tert-butyl (4-formylphenyl) carbonate, 4-
methoxybenzylamine, benzoic acid and cyclohexyl isocyanide. To a solution of tert-butyl (4-
formylphenyl) carbonate in ethanol/trifluorethanol (TFE) 1/1 under a stream of nitrogen, 4-
methoxybenzylamine was added. After 4 hours the carboxylic acid and cyclohexyl isocyanide were 
added. The reaction was stirred at room temperature for 48 h, after which, treatment of the reaction 
mixture gave Ugi adduct 1a' as a white solid in 94% yield (Scheme 11). The proton NMR spectrum 
of the compound gave the expected peaks with the diastereotopic CH2 protons of the benzylamine 
group appearing as two signals at 4.41 ppm and 4.63 ppm.  
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Scheme 11 – Synthesis of the cyclohexylamides of N-benzoyl and N-acetyl, N-(4-
metoxybenzylamino)-[4-(O-tert-butyloxycarbonyl)phenyl]-glycine (compounds 1a’ and 2a’). 
The Ugi adduct was treated with TFA to give compound 1a as a white solid with 34% yield 
(Scheme 12). The proton NMR spectrum did not exhibit the peaks corresponding to the 4-
methoxybenzyl group, previously cited, neither the peaks corresponding to the Boc group that 
typically appear as a singlet around 1.5 ppm. However, peaks corresponding to the 
cyclohexylamide were still present. Thus, removal of the hydroxyl protecting group tert-
butyloxycarbonyl (Boc) and of the 4-methoxybenzyl group occurred; however, the cyclohexylamide 
was maintained. 
 
Scheme 12 – Synthesis of the cyclohexylamides of N-benzoyl and N-acetyl, 4-(hydroxyphenyl)-
glycine (compounds 1a and 2a). 
To verify if the bulkiness of the aromatic ring of benzoic acid was responsible for lack of cleavage 
of the cyclohexylamide, the Ugi reaction was performed with acetic acid to give 2a' in quantitative 
yield as a light yellow oil (Scheme 12). Treatment of compound 2a’ with TFA, again resulted in 
removal of the Boc and the 4-methoxybenzyl groups, without cleavage of the cyclohexylamine 
(compound 2a, Scheme 12). Thus, treatment of Ugi adducts 1a' and 2a’ with TFA allowed the 
simultaneous removal of the tert-butyloxycarbonyl and the methoxybenzyl groups, without affecting 
the cyclohexylamide. This is in agreement with previous results by Maia et al. in the synthesis of 
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N-acyl--dialkylglycines by cleavage of Ugi adducts with neat TFA.95 Treatment in these conditions 
of N-benzoyl-N,α,α-trialkylglycine amides formed by reaction of 4-methoxybenzylamine, benzoic 
acid, cyclohexyl isocyanide and the more bulky dibenzylketone, resulted in removal of the 
methoxybenzyl group without amide cleavage. The authors reported that in neat TFA the N-alkyl 
group of the bulkier N-benzoyl, N-(4-methoxybenzyl) α,α-dibenzylglycine derivatives cleaves faster 
than their amide bond. They concluded that, for acidolytic cleavage of the C-terminal amide to 
occur, the presence of an alkyl/aryl substituent at the amino acid nitrogen atom is required. Thus, 
the phenyl group directly linked to the −carbon in adducts 1a' and 2a' seems to exert a steric 
effect comparable to that reported for the -dibenzyl moiety in N-acyl-N,α,α-trialkylglycine 
amides.  
Compound 1a could also be obtained in a one-pot procedure consisting of the condensation 
reaction, followed by evaporation of the solvent at reduced pressure and treatment of the residue 
with TFA (Scheme 13). Compound 1a was obtained in the one-pot procedure in 63% yield, while 
the overall yield of the two steps reaction was 34%. 
tert-Butyl (4-formyl-2-methoxyphenyl) carbonate and di-tert-butyl (4-formyl-1,2-phenylene) 
dicarbonate (Scheme 13, compounds b and c, respectively) were reacted in the same conditions 
to give N-benzoyl, 4-hydroxy-3-methoxy and 3,4-dihydroxy phenylglycine cyclohexylamides in 76% 
and 66% yields, respectively (compounds 1b and 1c, Scheme 13). 
 
 
Scheme 13 – One-pot synthesis of the cyclohexylamides of N-benzoyl, (hydroxyphenyl)glycines 
(compounds 1a, 1b and 1c). 
An attempt to carry out the condensation reaction using di-tert-butyl (3-formyl-1,2-phenylene) 
dicarbonate (compound d, Scheme 14) and benzoic acid gave only trace amounts of the 
corresponding Ugi adduct (compound 1d', Scheme 14). 
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Scheme 14 – Synthesis of the cyclohexylamide of N-benzoyl N-(4-metoxybenzylamino)-[2,3-(O-di-
tert-butyloxycarbonyl)phenyl]glycine (compound 1d’). 
This can be explained by the bulky Boc group in position 2, which causes high steric hindrance. 
Wang and Liu in a similar study, also obtained a low yield in Ugi adduct when they placed a bulky 
group at position 2 of the benzaldehyde. In this case, the yield in Ugi adduct was only 51%, which 
was significantly lower than the same reaction with an aldehyde with a hydrogen atom at position 
2, for which they obtained 83% yield.80 Due to the low yield in compound 1d’, attempts at treatment 
with TFA was not carried out. 
The one-pot reaction was carried out substituting 2-naphthylacetic acid for benzoic acid and 
using di-tert-butyl (4-formyl-1,2-phenylene) dicarbonate to give the N-(2-naphthyl)acetyl, (3,4-
dihydroxyphenyl)glycine amide in 78% yield (compound 3c, Scheme 15). 
 
 
Scheme 15 – One-pot synthesis of the cyclohexylamide of N-(2-naphthyl)acetyl (3,4-
dihydroxyphenyl)glycine (compound 3c). 
After obtaining good results in the syntheses carried out with carboxylic acids with only aromatic 
rings or a methyl group, it was decided to use carboxylic acids with a hydroxyl group, namely 4-
hydroxyphenylacetic acid and p-coumaric acid. Thus, to a solution of tert-butyl (4-formyl-2-
methoxyphenyl) carbonate in ethanol/2,2,2-trifluoroethanol, 4-methoxybenzylamine was added. 
After 4 hours, 4-hydroxyphenylacetic acid and cyclohexyl isocyanide were added and left to react 
to give the corresponding Ugi adduct 4b’ (Scheme 16) as a white solid with 97% yield. Then 
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trifluoroacetic acid was added to the adduct to give compound 4b (Scheme 16) as a light pale solid 
in 59% yield. 
 
 
Scheme 16 – Synthesis of the cyclohexylamides of N-(4-hydroxyphenyl)acetyl, (4-hydroxy, 3-
methoxyphenyl)glycine and (3,4-dihydroxyphenyl)glycine (compound 4b and 4c). 
The same procedure was carried out using the di-tert-butyl (4-formyl-1,2-phenylene) dicarbonate 
and 4-hydroxyphenylacetic acid to give compound 4c’ (Scheme 16) as a light brown oil with 92% 
yield. Cleavage with TFA gave compound 4c as a light orange oil with 80% yield. All the structures 
of these compounds were confirmed using 1H and 13C NMR spectroscopy. 
The same procedure was carried out using tert-butyl (4-formyl-2-methoxyphenyl) carbonate and 
p-coumaric acid to give the corresponding Ugi adduct 5b’ as a white solid with 83% yield. Treatment 
of the Ugi adduct with trifluoroacetic acid failed to give compound 5b. 
The results obtained led us to explore the possibility of adding a second catecholic function to 
the amino acid derivatives by using as carboxylic acid component a catecholic acid. These 
cathecolic acids were tested without hydroxyl protection, since when the acid component is added, 
all 4-methoxybenzylamine has been consumed. Thus, tert-butyl (4-formylphenyl) carbonate was 
reacted in the same conditions, substituting protocatechuic acid for benzoic acid to give the Ugi 
adduct 6a' in quantitative yield (Scheme 17). Treatment of compound 6a' with TFA gave the N-
protocatechoyl (4-hydroxyphenyl)glycine derivative in 72% yield (compound 6a, Scheme 17). By 
reacting tert-butyl (4-formyl-2-methoxyphenyl) carbonate or di-tert-butyl (4-formyl-1,2-phenylene) 
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dicarbonate with protocatechuic acid the corresponding N-protocatechoyl, (hydroxyphenyl)glycine 
amides were obtained in good yields (compounds 6b and 6c, respectively, Scheme 17).  
 
Scheme 17 – Synthesis of the cyclohexylamides of N-protocatechoyl, N-(3,4-dihydroxyphenyl)acetyl 
and N-hydrocaffeoyl, (4-hydroxy, 3-methoxyphenyl)glycine and (3,4-dihydroxyphenyl)glycine 
(compound 6a, 6b, 6c, 7b, 7c and 8c). 
The same procedure using 3,4-dihydroxyphenylacetic acid and tert-butyl (4-formyl-2-
methoxyphenyl) carbonate gave the corresponding Ugi adduct 7b’ as a white solid with 93% yield. 
Treatment of 7b’ with trifluoroacetic acid gave compound 7b as a white solid in 44% yield. Di-tert-
butyl (4-formyl-1,2-phenylene) dicarbonate was reacted in the same conditions to give the N-(3,4-
dihydroxyphenyl)acetyl, (3,4-dihydroxyphenyl)glycine derivative in 63% yield (compound 7c, 
Scheme 17). 
The one-pot reaction was carried out with hydrocaffeic acid and using di-tert-butyl (4-formyl-1,2-
phenylene) dicarbonate to give the N-hydrocaffeoyl (3,4-dihydroxyphenyl)glycine cyclohexylamide 
in 74% yield (compound 8c, Scheme 17). 
In order to test the possibility of obtaining a dipeptide derivative baring a (hydroxyphenyl)glycine 
residue, the reaction was carried out using as acid component N-benzyloxycarbonylglycine. Thus, 
reaction in the same conditions using di-tert-butyl (4-formyl-1,2-phenylene) dicarbonate and N-
benzyloxycarbonylglycine gave compound 9c’ as a light pink solid in 94% yield. Cleavage with TFA 
gave the cyclohexylamide of N-benzyloxycarbonylglycyl, (3,4-dihydroxyphenyl)glycine as a white 
solid in 74% yield (compound 9c, Scheme 18). 
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Scheme 18 – Synthesis of cyclohexylamide of N-benzyloxycarbonylglycyl, (3,4-
dihydroxyphenyl)glycine (compound 9c). 
Thus, a wide range of N-acyl (hydroxyphenyl)glycine amides could be obtained in good yields by 
reacting hydroxybenzaldehyde derivatives with 4-methoxybenzylamine, cyclohexyl isocyanide and 
benzoic acid, phenolic acids or catecholic acids to give Ugi adducts that were subsequently treated 
with trifluoroacetic acid (Scheme 19, Table 4). 
 
Scheme 19 – Synthesis of N-acyl (hydroxyphenyl)glycine amides. 
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Table 4 – Yields obtained in the synthesis of phenolic and catecholic Ugi adducts and in their 
treatment with trifluoroacetic acid to give N-acyl, (hydroxyphenyl)glycine amides. 
O-(tert-Butyloxycarbonyl) benzaldehyde Carboxylic acid 
Ugi 
adduct 
Yield 
(%) 
Cyclohexyla
mide of N-
acyl, 
(hydroxyphe
nyl)glycine  
Yield 
(%) 
tert-Butyl (4-formylphenyl) carbonate, a Benzoic acid, 1 1a’ 94 1a 34 
tert-Butyl (4-formyl-2-methoxyphenyl) 
carbonate, b 
Benzoic acid, 1 1b’ - 1b 76 
di-tert-Butyl (4-formyl-1,2-phenylene) 
dicarbonate, c 
Benzoic acid, 1 1c’ - 1c 66 
di-tert-Butyl (3-formyl-1,2-phenylene) 
dicarbonate, d 
Benzoic acid, 1 1d' 17 1d - 
tert-Butyl (4-formylphenyl) carbonate, a Acetic acid, 2 2a’ 
Quanti-
tative 
2a - 
di-tert-Butyl (4-formyl-1,2-phenylene) 
dicarbonate, c 
2-Naphtylacetic acid, 3 3c' - 3c 78 
tert-Butyl (4-formyl-2-methoxyphenyl) 
carbonate, b 
4-Hydroxyphenylacetic acid, 4 4b’ 97 4b 59 
di-tert-Butyl (4-formyl-1,2-phenylene) 
dicarbonate, c 
4-Hydroxyphenylacetic acid, 4 4c' 92 4c 80 
tert-Butyl (4-formyl-2-methoxyphenyl) 
carbonate, b 
p-Coumaric acid, 5 5b’ 83 5b - 
tert-Butyl (4-formylphenyl) carbonate, a Protocatechuic acid, 6 6a' 
Quanti-
tative 
6a 72 
tert-Butyl (4-formyl-2-methoxyphenyl) 
carbonate, b 
Protocatechuic acid, 6 6b’ 
Quanti-
tative 
6b 68 
di-tert-Butyl (4-formyl-1,2-phenylene) 
dicarbonate, c 
Protocatechuic acid, 6 6c’ - 6c 69 
tert-Butyl (4-formyl-2-methoxyphenyl) 
carbonate, b 
3,4-diHydroxyphenylacetic acid, 7 7b' 93 7b 44 
di-tert-Butyl (4-formyl-1,2-phenylene) 
dicarbonate, c 
3,4-diHydroxyphenylacetic acid, 7 7c' 86 7c 63 
di-tert-Butyl (4-formyl-1,2-phenylene) 
dicarbonate, c 
Hydrocaffeic acid, 8 8c' - 8c 74 
di-tert-Butyl (4-formyl-1,2-phenylene) 
dicarbonate, c 
N-Benzyloxycarbonylglycine acid, 9 9c' 94 9c 74 
 
2.2. DPPH Radical Essay 
The DPPH radical assay method is one of most commonly used to evaluate the antiradicalar ability 
of compounds and measures their reactivity with the stable free radical, 2,2-diphenyl-1-
picrylhydrazyl (Figure 12). 
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Figure 12 – Chemical structure of 2,2-diphenyl-1-picryl-hydrazyl radical (DPPH•). 
The DPPH• radical exhibits a maximum absorption at 515 nm (methanolic solutions of the 
radical have a strong violet colour). However, after reduction by an antioxidant or a radical species 
(R•), a decrease in the absorbance at that wavelength is observed. When the unpaired electron of 
the DPPH• nitrogen atom receives a hydrogen atom from the antioxidant compound, colour change 
occurs (Figure 13).60 
Figure 13 – Mechanism of DPPH reaction with antioxidant.60 
Determination of the radical-scavenging activity of the N-acyl (hydroxyphenyl)glycines was 
carried out using 1,1-diphenyl-2-picrylhydrazyl (DPPH•) as a stable radical.96 For each compound 
the EC50 values (relative concentration of antioxidant required to lower the initial DPPH• 
concentration by 50%) were determined after several reaction times and compared to the values 
obtained for protocatechuic acid. 
As expected, the radical-scavenging activity of the monophenol derivative 1a was very weak. 
However, a significant increase in activity occurs when a methoxy group is added in ortho position 
to the hydroxyl group (compound 1b) (a six-fold increase for EC50 determined after 5 minutes). The 
substitution of this methoxy group by another hydroxyl group (compound 1c), increases more than 
ten times the radical-scavenging activity. A slightly higher activity is observed when (2-
naphthyl)acetyl is substituted for benzoyl as N-acyl group (compound 3c). The N-protocatechoyl 4-
hydroxylphenylglycine derivative (compound 6a) showed radical-scavenging activity comparable to 
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that of compound 1c, which also has an ortho-dihydroxyaryl function as amino acid side chain. 
Introduction of a methoxy group in ortho position to the hydroxyl group (compound 6b) causes a 
25% increases in activity as determined after 5 minutes. Substitution of the methoxy group with a 
second hydroxyl group (compound 6c) causes a further 30% increase in activity. The N-
hydrocaffeoyl 3,4-dihydroxyphenylglycine derivative (compound 8c) showed similar activity to the 
N-protocatechoyl derivative 6c. The radical-scavenging activities of compounds 6c and 8c were 
almost double the activities of derivatives with a single catecholic group (compounds 1c or 6a).  
These results show a direct correlation between radical-scavenging capacity against the 
hindered DPPH radical and the number of hydroxyl or catechol groups present in the glycine 
derivatives. A high increase in activity with the increase in number of hydroxyl or catechol groups 
is observed with the monocatecholic derivatives (compounds 1c and 6a) having twice the radical-
scavenging activity of protocatechuic acid, while the N-catechoyl derivatives 6c and 8c have almost 
four times this activity. Thus, the introduction of the catecholic moiety in an amino acid structure 
induces a significant increase in its intrinsic radical scavenging activity. 
 
2.3. Synthesis of phenolic and catecholic derivatives of dehydrophenylalanine 
Amino acids coupled with phenolic acids and/or phenolic amines can be obtained from natural 
sources such as fruits, vegetables, and beverages, or synthetically. It is assumed that these 
bioactive substances are involved in suppression of deleterious effects of oxidative stress and have 
a wide range of biological activities such as as antioxidant,3,47-50 anticancer4 and antimicrobial.5, 51-55 
Studies have confirmed that molecular combinations improve the antioxidant efficiency of 
natural antioxidants and can be useful to investigate structure activity relationships. For example, 
phenolic acid-amino acid and phenolic acid-amino acid-dopamine conjugates have shown to 
improve the antioxidant activity of natural amino acids due to the presence of phenolic functions.46 
Dehydroamino acids constitute an important class of non-proteinogenic amino acids with 
various biological activities, including antioxidant.29 A strategy in which dehydroamino acids are 
coupled with phenolic or catecholic acids and/or phenolic or catecholic amines could yield 
compounds with enhanced antioxidant activities. 
An efficient method for the synthesis of dehydroamino acids was developed by Ferreira et al. 
and has been used to prepare a wide range of dehydroamino acid derivatives.88-90 Herein, we 
propose to explore this method in order to obtain combinations of a dehydroamino acid with 
phenolic and catecholic amines and with phenolic acids. Thus, we proposed the synthesis of 
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phenoyl amides of N-phenoyl dehydrophenylalanine and to compare their antioxidant activities with 
the corresponding derivatives of the saturated amino acid phenylalanine.  
The following combinations of N-acyl dehydrophenylalanine and phenyalanine amides were 
prepared: 
 
2.3.1 Synthesis of N-(tert-butyloxycarbonyl) dehydrophenylalanine 
In order to obtain an N-acyl dehydrophenyalanine derivative that could be coupled with phenolic 
or catecholic amines, N-(tert-butyloxycarbonyl) dehydrophenylalanine was prepared.  
The methyl ester of N-(tert-butyloxycarbonyl) phenylserine was reacted with tert-
butyldicarbonate (Boc2O) and 4-dimethylaminopyridine (DMAP) as catalyst, followed by treatment 
with N,N,N’,N’-tetramethylguanidine (TMG).90 Thus, to a solution of the methyl ester of N-(tert-
butyloxycarbonyl) phenylserine in dry acetonitrile, 0.11 equivalent of DMAP were added, followed 
by 1.1 equivalents of Boc2O under rapid stirring at room temperature. After stirring for 16 hours 
the reaction mixture was treated with 2% in volume of N,N,N’,N’-tetramethylguanidine (TMG) to 
give the methyl ester of N-(tert-butyloxycarbonyl) dehydrophenylalanine (compound 11, Scheme 
20) as a white solid in 98% yield. 
 
Scheme 20 – Synthesis of N-(tert-butyloxycarbonyl) dehydrophenylalanine. 
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Removal of the methyl ester was carried out by treating compound 11 in dioxane/ NaOH (1 
mol.dm-3) under rapid stirring at room temperature, to give N-(tert-butyloxycarbonyl) 
dehydrophenylalanine (compound 12, Scheme 20) as a white solid in 96% yield. 
 
2.3.2. Synthesis of the phenoyl amides of N-(tert-butyloxycarbonyl) dehydrophenylalanine 
and phenylalanine 
Coupling of N-(tert-butyloxycarbonyl) dehydrophenylalanine with phenoyl amines was carried 
out using HOBt/HBTU as coupling agents. Thus, compound 12 was dissolved in acetonitrile 
and 1.0 equivalent of HOBt added, followed by addition of 1.0 equivalent of HBTU and 1.0 
equivalent of 4-hydroxybenzylamine. After reacting for 18 h treatment of the reaction mixture gave 
the 4-hydroxybenzylamide of N-(tert-butyloxycarbonyl) dehydrophenyalanine (compound 12a, 
scheme 21) as a yellow oil in 88% yield. 
 
Scheme 21 - Synthesis of the 4-hydroxybenzylamide and the dopamide of N-(tert-butyloxycarbonyl) 
dehydrophenylalanine. 
The same procedure using dopamine hydrochloride gave the dopamide of N-(tert-
butyloxycarbonyl) dehydrophenyalanine (compound 12b, Scheme 21) as a light yellow solid in 97% 
yield. 
In order to obtain the saturated references, N-(tert-butyloxycarbonyl) phenylalanine was reacted 
with 4-hydroxybenzylamine and dopamine in the same conditions, giving compounds 13a and 13b 
in 94% and 91% yield, respectively (Scheme 22). 
 
Scheme 22 - Synthesis of the 4-hydroxybenzylamide and the dopamide of N-(tert-butyloxycarbonyl) 
phenylalanine. 
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2.3.3. Synthesis of a phenoyl amide of N-protocatechoyl dehydrophenylalanine and 
phenylalanine 
In order to conjugate the phenoyl amides of dehydrophenylalanine with phenolic acids, cleavage 
of the amine protecting group of compounds 12a and 12b was carried out. Thus, the 4-
hydroxybenzylamide of N-(tert-butyloxycarbonyl) dehydrophenyalanine was treated with TFA. 
Removal of the solvent at reduced pressure gave the 4-hydroxybenzylamide of 
dehydrophenyalanine trifluorate (compound 14a, Scheme 23) in 99% yield. 
 
Scheme 23 – Synthesis of the 4-hydroxybenzylamide and the dopamide of dehydrophenylalanine 
trifluorate. 
The same reaction using compound 12b as substrate gave the corresponding dopamide 
derivative in quantitative yield (compound 14b, Scheme 23). 
The unprotected dehydrophenylalanine derivatives could now be reacted with a phenolic acid 
to give phenolic acid-dehydrophenylalanine-amine conjugates. Thus, compound 14a was reacted 
with protocatechuic acid using HOBt/HBTU as coupling agents to give the 4-hydroxybenzylamide 
of N-protocatechoyl dehydrophenylalanine (compound 15a, Scheme 24) as a yellow oil in 75% 
yield. 
  
Scheme 24 – Synthesis of the 4-hydroxybenzylamide of N-protocatechoyl dehydrophenylalanine. 
The corresponding phenylalanine derivative of compound 15a was obtained by treatment of 
compound 13a with TFA to give compound 16a (Scheme 25) as a white solid in 85% yield. Coupling 
of 16a with protocatechuic acid gave the 4-hydroxybenzylamide of N-protocatechoyl phenylalanine 
(compound 17a, Scheme 25) as a light yellow solid in 65% yield. 
2. Results and discussion 
44 
 
 
Scheme 25 – Synthesis of the 4-hydroxybenzylamide of N-protocatechoyl phenylalanine. 
Thus, a wide range of hydroxyphenylamides of N-phenoyl dehydrophenylalanine and phenylalanine 
can be obtained in good yields by coupling N-(tert-butyloxycarbonyl) dehydrophenylalanine with 
phenolic or catecholic amines. Subsequently, these dehydrophenylalanine derivatives are 
submitted to cleavage of the Boc group and coupling with phenolic acids (Table 5). 
Table 5 – Yields obtained in the synthesis of hydroxyphenylamides of N-acyl dehydrophenylalanine 
and phenylalanine derivatives. 
Reagent Product Yield (%) 
Boc-Phe-OH, 12 Boc-Phe-NH-Bzl(4-OH), 12a 88 
Boc-Phe-OH, 13 Boc-Phe-NH-Bzl(4-OH), 13a 94 
Boc-Phe-OH, 12 Boc-Phe-NH-Dopa, 12b 97 
Boc-Phe-OH, 13 Boc-Phe-NH-Dopa, 13b 91 
Tfa.H-Phe-NH-Bzl(4-OH), 14a Bz(3,4-OH)-Phe-NH-Bzl(4-OH), 15a 75 
Tfa.H-Phe-NH-Bzl(4-OH), 16a Bz(3,4-OH)-Phe-NH-Bzl(4-OH), 17a 65 
 
2.3.4. Synthesis of the 4-hydroxybezylamide of a N-acyl dehydrotripeptide  
Some drugs are ubiquitous in the management of many diseases and injuries. However, even 
these well-established medications can cause stomach ulcers and other gastrointestinal disorders. 
Side effects most commonly arise when the drugs are taken for an extended period. One way of 
preventing these painful consequences is to encapsulate drugs to restrict their availability in certain 
parts of the body and target their release to others. 
Small peptides with aromatic side chains, aromatic N-acyl groups or aromatic amides have 
been known to self-assemble into gel type structures such as hydrogels. These hydrogels have 
been studied as vehicles for drug loading and release, such as anti-inflammatory agents. One such 
agent is naproxen. It is well-established that naproxen covalently bound to peptides plays an 
adjuvant role in self-assembly driven by hydrophobic interactions in water. Naproxen is so 
successful in co-assembly due to its structure with two fused aromatic rings (Figure 14), as well as 
similar derivatives of the naphthalene unit.97 
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Figure 14 – Structure of Naproxen. 
In order to obtain a tripeptide baring a dehydrophenylalanine residue, a phenolic amide and 
naproxen as acylating group, compound 16a was reacted with N-naproxoyl-alanil-
dehydrophenylalanine. The tripeptide Npx-Ala-Phe-Phe-NH-Bzl(4-OH) (compound 18a, Scheme 
26) was obtained as a white solid in 70% yield. 
 
Scheme 26 – Synthesis of Npx-Ala-Phe-Phe-NH-Bzl(4-OH).  
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In this work, the synthesis of phenolic and catecholic Ugi adducts and the corresponding amides 
of N-acyl (hydroxyphenyl)glycines is described. 
The Ugi adducts were obtained in high yields (83%-97%) by the Ugi reaction using different O-
(tert-butyloxycarbonyl) benzaldehydes, namely, tert-butyl (4-formylphenyl) carbonate, tert-butyl (4-
formyl-2-methoxyphenyl) carbonate and di-tert-butyl (4-formyl-1,2-phenylene) dicarbonate; and 
different carboxylic acids, namely, benzoic acid, acetic acid, 2-naphtylacetic acid, 4-
hydroxyphenylacetic acid, p-coumaric acid, protocatechuic acid, 3,4-dihydroxyphenylacetic acid, 
hydrocaffeic acid and N-benzyloxycarbonylglycine.  
An attempt to carry out the condensation reaction using di-tert-butyl (3-formyl-1,2-phenylene) 
dicarbonate and benzoic acid gave only 17% of the corresponding Ugi adduct. This was attributed 
to the position of the bulky tert-butyloxycarbonyl group which causes high steric hindrance. 
The Ugi adducts were treated with TFA, which led to removal of the hydroxyl protecting tert-
butyloxycarbonyl group and of the 4-methoxybenzyl group. However, the cyclohexylamide was 
maintained. Thus, the corresponding cyclohexylamides of (hydroxyphenyl)glycine were obtained in 
yields between 34% and 80%. The stability of the cyclohexylamide relatively to treatment with neat 
TFA seems to result from the steric effect produced by the phenyl group directly linked to the 
−carbon. This steric effect is comparable to that reported for the -dibenzyl moiety in N-acyl-
N,α,α-trialkylglycine amides.95 
The DPPH method was used to study and evaluate the antiradical capacity of some of the 
compounds synthesized. The results show a high increase of activity with the increase in number 
of hydroxyl or catechol groups. The monocatecholic derivatives have twice the radical-scavenging 
activity of protocatechuic acid, while the dicatecholic derivatives have almost four times this activity. 
Thus, the introduction of the catecholic moiety in an amino acid structure induces a significant 
increase in its intrinsic radical scavenging activity. 
The synthesis of hydroxyphenylamides of N-(tert-butyloxycarbonyl) dehydrophenylalanine was 
also carried out. To obtain an N-acyl dehydrophenyalanine derivative that could be coupled with 
phenolic or catecholic amines, N-(tert-butyloxycarbonyl) dehydrophenylalanine was prepared. Then, 
N-(tert-butyloxycarbonyl) dehydrophenylalanine was coupled with a phenolic or a catecholic amine 
to give the 4-hydroxybenzylamide or the dopamide of N-(tert-butyloxycarbonyl) 
dehydrophenylalanine, respectively. The corresponding derivatives of the saturated amino acid 
phenylalanine were also prepared. These compounds were obtained in yields between 88% and 
97%. 
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To enable the synthesis of hydroxyphenylamides of N-protocatechoyl dehydrophenylalanine, 
cleavage of the amine protecting group with TFA was carried out to give the 4-hydroxybenzylamide 
of dehydrophenylalanine trifluorate. Then, the dehydrophenylalanine derivative was coupled with 
protocatechuic to give the 4-hydroxybenzylamide of N-(protocatechoyl) dehydrophenylalanine. The 
corresponding derivative of the saturated amino acid phenylalanine was also prepared.  
Thus, it was possible to prepare phenoyl and catechoyl amides of N-(tert-butyloxycarbonyl) 
dehydrophenylalanine and subsequently, in the case of the 4-hydroxybenzylamide 
dehydrophenylalanine derivative, conjugate it with protocatechuic acid. 
These novel compounds can have important biological activities resulting from the synergic 
effects of both the catechol and the dehydro moieties. However, due to time constraints, it was not 
possible to perform biological tests for any of these compounds. Thus, as future perspectives, it is 
proposed to test the antioxidant/antiradicalar activity of the compounds obtained, to understand if 
the dehydro moiety has a high influence on the antioxidant activity. 
A 4-hydroxybenzylamide tripeptide baring a dehydrophenylalanine residue and having naproxen 
as N-acyl group was also synthesized. This was carried out by coupling N-naproxoyl-alanil-
dehydrophenylalanine with the 4-hydroxybenzylamide of phenylalanine to give the 4-
hydroxybenzylamide of a N-naproxoyl dehydrotripeptide in 70% yield. 
It was not possible to perform any tests with this compound, but it is known that naproxen is 
an excellent anti-inflammatory agent. It can be inserted into peptide-based hydrogels with potential 
in various bioengineering applications such as vehicles for transporting and releasing drugs into 
the body. As future perspectives tests should be carried out to confirm if this tripeptide can be used 
for this purpose. 
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4.1.General methods 
Melting points (ºC) were determined in a Gallenkamp apparatus and are uncorrected. 1H and 
13C NMR spectra were recorded on a Bruker Avance II+ at 400 and 100.6 MHz, respectively. 1H-1H 
spin-spin decoupling, DEPT  45º, HMQC and HMBC were used to attribute some signals. In the 
description of each NMR spectrum, the data are indicated in the following order: chemical shift (δ) 
in parts per million (ppm), multiplicity of signal [s (singlet), d (doublet), q (quartet), m multiplet)], 
coupling constant (J) in Hertz (Hz), number of protons (nH), proton identification. The chemical 
shifts indicated for each compound were recorded relative to the internal standard which is 
comprised of the solvent used for spectrum acquisition. HRMS data were recorded by the 
Laboratory for Structural Elucidation of the Materials Centre of the University of Porto on an LTQ 
OrbitrapTM XL hybrid mass spectrometer (Thermo Fischer Scientific, Bremen, Germany) controlled 
by LTQ Tune Plus 2.5.5 and Xcalibur 2.1.0. Elemental analysis was performed on a LECO CHNS 
932 elemental analyzer. The reactions were monitored by thin layer chromatography (TLC). 
Column chromatography was performed on Macherey-Nagel silica gel 230-400 mesh. Petroleum 
ether refers to the boiling range 40-60 ºC. Most of the solvents used had a purity of p.a., so they 
were used without prior purification. The exception was acetonitrile which was dried by stirring with 
silica at room temperature overnight, refluxed with calcium hydride and distilled into a vial with 
drying agents.  
 
4.2. DPPH Radical Essay 
DPPH radical-scavenging activity was assessed according to standard procedures.60,96 A 
methanolic DPPH· stock solution (1.93 mmol.dm-3) was diluted to give a 0.10 mmol dm-3 working 
solution. The reaction between DPPH· and each AO was monitored at 515 nm by using a 
Powerwave XS Microplate Reader (Bio-Tek Instruments, Inc) thermostated at T = 25.0  0.1ºC. 
The wells of a 96-well microplate contained a methanolic solution of the AO (3-200 µmol.dm-3) and 
80 µmol.dm-3 DPPH·. The absorbance of each well was recorded at 1 min intervals for a 60 min 
period. The absorbance of each solution was subtracted from the blank (80 µmol.dm-3 DPPH· 
without AO). The antiradical activity was defined as the relative concentration of antioxidant required 
to lower the initial DPPH concentration by 50% [EC50 (mol/L phenolic compound per unit DPPH 
concentration)]. 
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4.3. Statistical analysis 
All the DPPH• radical scavenging assays were run at least in quadruplicate. SPSS 21.0 
software was used for statistical analysis by one-way analysis of variance (ANOVA, with Tukey’s 
HSD multiple comparison) with the level of significance set at P<0.05. Data are presented as 
means  standard deviation. 
 
4.4. Synthesis 
4.4.1. Synthesis of phenolic and catecholic amino acid derivatives by the modified 
multicomponent Ugi reaction 
Procedure A: Synthesis of O-tert-butyloxycarbonylated benzaldehydes. 
To a solution of the hydroxybenzaldehyde (5.00 mmol) in dry acetonitrile (0.20 mol.dm -3), 0.10 
equiv. of dimethylaminopyridine was added. This was followed by addition under rapid stirring at 
room temperature of 1.10 equiv. of tert-butyldicarbonate for the monohydroxylated benzaldehydes 
and 2.20 equiv. for the dihydroxylated benzaldehydes. When all the reactant had been fully tert-
butyloxycarbonylated the solvent was evaporated at reduced pressure and the residue dissolved in 
ethyl acetate (100 cm3) and washed with KHSO4 (1 mol.dm-3) and brine (3 times 25 cm-3 each). 
The organic layer was dried with MgSO4 and the solvent evaporated at reduced pressure. 
Procedure B: Two step synthesis of the cyclohexylamides  of N-acyl, (hydroxyphenyl)glycine. 
To a solution of the O-tert-butyloxycarbonylated benzaldehyde (1.00 mmol) in ethanol/2,2,2-
trifluoroethanol (1/1) (0.17  mol.dm-3) under a stream of nitrogen, 1.10 equiv. of 4-
methoxybenzylamine was added. After stirring for 4 hours, 1.10 equiv. of the carboxylic acid and 
1.10 equiv. of cyclohexyl isocyanide were added and left to react for 2 days. The reaction mixture 
was then evaporated at reduced pressure and the residue was dissolved in ethyl acetate (100 cm3) 
and washed with KHSO4 (1 mol.dm-3), NaHCO3 (1 mol.dm-3) and brine (3 times 25 cm3 each). The 
organic layer was dried with MgSO4 and the solvent evaporated at reduced pressure to give the 
corresponding Ugi adduct. Trifluoroacetic acid was added to the adduct (0.25 mol.dm -3) and the 
solution refluxed at 80 °C for 10 min. TFA was then evaporated at reduced pressure. 
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Procedure C: One-pot synthesis of of the cyclohexylamides  of N-acyl (hydroxyphenyl)glycine 
cyclohexylamides. 
To a solution of the O-tert-butyloxycarbonylated benzaldehyde (1.00 mmol) in ethanol/2,2,2-
trifluoroethanol (1/1) (0.17  mol.dm-3), 1.10 equiv. of 4-methoxybenzylamine was added under a 
stream of nitrogen. After 4 hours, 1.10 equiv. of the carboxylic acid and 1.10 equiv. of cyclohexyl 
isocyanide were added and left to react for 2 days. The reaction mixture was then evaporated at 
reduced pressure and trifluoroacetic acid added to the residue (0.25 mol.dm -3). The solution was 
refluxed at 80 °C for 10 min. after which TFA was evaporated at reduced pressure. 
 
4.1.1.1. Synthesis of O-tert-butyloxycarbonylated benzaldehydes 
Synthesis of tert-butyl (4-formylphenyl) carbonate, a92 
Procedure A was followed using 4-hydroxybenzaldehyde to give compound a (1.07 g, 96%) as 
a white solid (from diethyl ether/n-hexane). M.p. 73.0-74.0 °C. 
1H NMR (400 MHz, CDCl3): δ = 1.58 [s, 9H, C(CH3)3], 6.36 (d, J = 6.8 Hz, 2H, ArH), 7.92 (d, J = 
6.8 Hz, 2H, ArH), 10.00 (s, 1H, CHO) ppm. 
Synthesis of tert-butyl (4-formyl-2-methoxyphenyl) carbonate, b93 
Procedure A was followed using 4-hydroxy-3-methoxybenzaldehyde to give compound b (1.20 
g, 95%) as a white solid (from diethyl ether/n-hexane). M.p. 87.0-88.0 °C. 
1H NMR (400 MHz, CDCl3): δ = 1.57 [s, 9H, C(CH3)3], 3.94 (s, 3H, OCH3), 7.31 (d, J = 8.0 Hz, 
1H, ArH), 7.48 (dd, J = 8.0 Hz, J = 2.0 Hz, 2H, ArH), 7.51 (d, J = 2.0 Hz, 1H, ArH), 9.95 (s, 1H, 
CHO) ppm 
Synthesis of di-tert-butyl (4-formyl-1,2-phenylene) dicarbonate, c94 
Procedure A was followed using 3,4-dihydroxybenzaldehyde to give compound c (1.57 g, 93%) 
as a light brown oil. 
1H NMR (400 MHz, CDCl3): δ = 1.55 [s, 18H, 2C(CH3)3], 7.45 (d, J = 8.0 Hz, 1H, ArH), 7.77 (dd, 
J = 8.0 Hz, J = 1.6 Hz, 1H, ArH), 7.80 (d, J = 1.6 Hz, 1H, ArH), 9.95 (s, 1H, CHO) ppm. 
Synthesis of di-tert-butyl (3-formyl-1,2-phenylene) dicarbonate, d 
Procedure A was followed using 2,3-dihydroxybenzaldehyde was followed to give compound d 
(1.62 g, 96%) as a light brown solid. M.p. 58.0-59.0 °C. 
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1H NMR (400 MHz, CDCl3): δ = 1.56 [s, 18H, 2C(CH3)3], 7.36-7.40 (m, 1H, ArH), 7.53 (dd, J = 
8.0 Hz, J = 1.6 Hz, 1H, ArH), 7.75 (dd, J = 8.0 Hz, J = 1.6 Hz, 1H, ArH), 10.19 (s, 1H, CHO) 
ppm.  
13C NMR (100.6 MHz, CDCl3): δ = 27.11 [C(CH3)3], 27.14 [C(CH3)3], 83.94 [C(CH3)3], 84.37 
[C(CH3)3], 126.07 (CH), 126.39 (CH), 128.53 (CH), 129.35 (C), 143.08 (C), 143.74 (C) 149.67 
(C=O), 149.99 (C=O), 187.27 (CH=O) ppm. 
HRMS (ESI): m/z M+ calcd for C17H22O7: 338.1366; found: 338.1597. 
 
4.4.1.2. Synthesis of Ugi adducts 
Synthesis of the cyclohexylamide of N-benzoyl, N-(4-metoxybenzylamino)-[4-O-tert-
butyloxycarbonyl)phenyl]glycine, 1a' 
Procedure B was followed using tert-butyl (4-formylphenyl) carbonate and benzoic acid to give 
the Ugi adduct 1a' (0.54 g, 94%) as a white solid (from diethyl ether). M.p. 65.0-66.0 °C.  
1H NMR (400 MHz, CDCl3): δ = 0.86-1.93 (m, 10H, CH2 cyclohexyl), 1.57 [s, 9H, C(CH3)3], 3.76 
(s, 3H, OCH3), 3.79-3.82 (m, 1H, CH cyclohexyl), 4.41 (br. s, 1H, C6H4CH2), 4.63 (br. s, 1H, 
C6H4CH2), 5.40 (br. s, 1H, CH), 5.74 (br. s, 1H, NH), 6.74 (d, J = 8.4 Hz, 2H, ArH), 7.00 (br. d, 
J = 4.8 Hz, 2H, ArH), 7.13 (d, J = 8.8 Hz, 2H, ArH), 7.35-7.37 (m, 4H, ArH), 7.46-7.49 (m, 3H, 
ArH) ppm.  
13C NMR (100.6 MHz, CDCl3): δ = 24.70 (CH2), 24.78 (CH2), 25.44 (CH2), 27.66 [C(CH3)3], 32.69 
(2CH2), 48.64 (CH cyclohexyl), 55.20 (OCH3), 64.08 (CH), 65.82 (C6H4CH2), 83.80 [C(CH3)3], 
113.87 (3CH), 121.61 (3CH), 126.68 (CH), 128.38 (CH), 128.49 (CH), 129.84 (CH), 130.07 
(CH), 130.70 (CH), 132.65 (2C), 133.35 (CH), 136.08 (C), 151.08 (C), 151.54 (C), 158.76 
(C=O), 168.04 (C=O), 173.07 (C=O) ppm.  
Anal. calcd. for C34H40N2O6 (572.69): C 71.31, H 7.04, N 4.89; found C 71.39, H 7.32, H 4.51.  
Synthesis of the cyclohexylamide of N-benzoyl, N-(4-metoxybenzylamino)-[2,3-di(O-tert-
butyloxycarbonyl)phenyl]glycine, 1d' 
Procedure B was followed using di-tert-butyl (3-formyl-1,2-phenylene) dicarbonate and benzoic 
acid. The residue obtained was chromatographed through silica using ethyl acetate/petroleum 
ether as eluent to give the Ugi adduct 1d' (0.12 g, 17%) as a light yellow oil. 
1H NMR (400 MHz, CDCl3): δ = 1.15-1.96 (m, 10H, CH2 cyclohexyl), 1.46, 1.57 [2s, 18H, C(CH3)3], 
3.79 (br. s, 4H, OCH3 + CH cyclohexyl), 4.25 (d, J = 4.8 Hz, 2H, C6H4CH2), 4.80 (br. s, 1H, CH), 
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5.92 (br. d, J = 7.6 Hz, 1H, NH), 6.86 (d, J = 8.8 Hz, 2H, ArH), 6.94 (t, J = 8.0 Hz, 1H, ArH), 
7.14 (dd, J = 8.0 Hz, J = 1.6 Hz, 1H, ArH), 7.18-7.22 (m, 3H, ArH), 7.47 (t, J = 8.0 Hz, 2H, ArH), 
7.59 (t, J = 7.2 Hz, 1H, ArH), 8.01 (dd, J = 8.0 Hz, J = 1.2 Hz, 2H, ArH) ppm. 
13C NMR (100.6 MHz, CDCl3): δ = 24.59 (CH2), 24.69 (CH2), 25.47 (CH2), 27.57 [C(CH3)3], 28.38 
[C(CH3)3], 32.91 (2CH2), 48.06 (CH cyclohexyl), 55.26 (OCH3), 58.43 (C6H4CH2), 82.02 [2C(CH3)3], 
113.96 (2CH), 119.46 (CH), 120.20 (CH), 120.56 (C), 121.56 (CH), 124.29 (CH), 128.49 (2CH), 
128.79 (CH), 129.49 (2CH), 129.62 (C), 130.51 (C), 130.87 (CH), 130.94 (C), 130.97 (C), 
133.18 (CH), 144.88 (C), 158.89 (2C=O), 168.82 (C=O), 172.00 (C=O) ppm. 
HRMS (ESI): m/z M+ calcd for C39H48N2O9: 688.3360; found: 688.3968. 
Synthesis of the cyclohexylamide of N-acetyl, N-(4-metoxybenzylamino)-[4-(O-tert-
butyloxycarbonyl)phenyl]glycine, 2a' 
Procedure B was followed using tert-butyl (4-formylphenyl) carbonate and acetic acid to give the 
Ugi adduct 2a' in quantitative yield as a light yellow oil. 
1H NMR (400 MHz, CDCl3): δ = 1.01-1.15 (m, 3H, CH2 cyclohexyl), 1.20-1.48 (m, 3H, CH2 
cyclohexyl), 1.54 [s, 9H, C(CH3)3], 1.56-1.69 (m, 2H, CH2 cyclohexyl), 1.81-1.93 (m, 2H, CH2 
cyclohexyl), 2.08 (s, 3H, CH3CO), 3.68-3.78 (m, 4H, NHCH + OCH3), 4.46 (d, J = 17.2 Hz, 1H, 
NCH2), 4.65 (d, J = 17.2 Hz, 1H, NCH2), 5.83 (br. s, 2H, CH + NH), 6.74 (d, J = 8.4 Hz, 2H, 
ArH), 6.91 (d, J = 8.4 Hz, 2H, ArH), 7.08 (d, J = 8.4 Hz, 2H, ArH), 7.36 (d, J = 8.4 Hz, 2H, ArH) 
ppm.  
13C NMR (100.6 MHz, CDCl3): δ = 22.36 (CH3), 24.65 (CH2), 24.71 (CH2), 25.36 (CH2), 27.58 
[C(CH3)3], 32.61 (2CH2), 48.60 (CH cyclohexyl), 50.35 (C6H4CH2), 55.13 (OCH3), 62.04 (CH), 
83.73 [C(CH3)3], 113.83 (2CH), 121.44 (2CH), 127.32 (2CH), 129.08 (C), 130.70 (2CH), 132.68 
(C), 150.98 (C), 151.47 (C), 158.56 (C=O), 168.43 (C=O), 172.63 (C=O) ppm. 
HRMS (ESI): m/z [M + H]+ calcd for C29H39N2O6: 511.2808; found: 511.2796. 
Synthesis of the cyclohexylamide of N-(4-hydroxyphenyl)acetyl, N-(4-methoxybenzylamino)-[4-(O-
tert-butyloxycarbonyl), 3-methoxyphenyl]glycine, 4b' 
Procedure B was followed using tert-butyl (4-formyl-2-methoxyphenyl) carbonate and 4-
hydroxyphenylacetic acid to give the Ugi adduct 4b’ (0.61 g, 97%) as a white solid (from ethyl 
acetate/petroleum ether). M.p. 141.0-143.0 °C. 
1H NMR (400 MHz, CDCl3): δ = 1.05-1.10 (m, 3H, CH2 cyclohexyl), 1.25-1.32 (m, 3H, CH2 
cyclohexyl), 1.54 [s, 9H, C(CH3)3], 1.57-1.63 (m, 2H, CH2 cyclohexyl), 1.87-1.89 (m, 2H, CH2 
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cyclohexyl), 3.57-3.69 (m, 3H, NHCH + CH2 acetyl), 3.76 (s, 3H, OCH3), 4.48 (br. d, J = 17.2 Hz, 
1H, C6H4CH2), 4.71 (br. d, J = 17.2 Hz, 1H, C6H4CH2), 5.75 (s, 1H, NH), 5.92 (br. s, 1H, αCH), 
6.66 (d, J = 8.4 Hz, 2H, ArH), 6.75 (d, J = 8.4 Hz, 2H, ArH), 6.90-7.01 (m, 7H, ArH) ppm.  
13C NMR (100.6 MHz, CDCl3): δ = 24.18 (CH2), 24.66 (CH2), 24.74 (CH2), 25.38 (CH2), 27.58 
[C(CH3)3], 32.55 (CH2), 40.35 (CH2C6H3), 48.85 (CH cyclohexyl), 55.22 (OCH3), 55.92 (OCH3), 
60.40 (C6H4CH2), 83.66 [C(CH3)3], 113.96 (2CH), 114.02 (CH), 115.68 (2CH), 122.03 (CH), 
122.55 (2CH), 125.64 (C), 127.51 (2CH), 129.05 (C), 130.00 (2CH), 133.64 (C), 140.25 (C), 
151.23 (C), 155.48 (C), 158.72 (C), 168.56 (C=O), 171.21 (C=O), 173.78 (C=O) ppm. 
Synthesis of the cyclohexylamide of N-(4-hydroxyphenyl)acetyl, N-(4-metoxybenzylamino)-[3,4-(O-
di-tert-butyloxycarbonyl)phenyl]glycine, 4c' 
Procedure B was followed using di-tert-butyl (4-formyl-1,2-phenylene) dicarbonate and 4-
hydroxyphenylacetic acid to give the Ugi adduct 4c’ (0.66 g, 92%) as a light brown oil. 
1H NMR (400 MHz, CDCl3): δ = 1.05-1.11 (m, 3H, CH2 cyclohexyl), 1.25-1.33 (m, 3H, CH2 
cyclohexyl), 1.54 [s, 18H, 2C(CH3)3], 1.57-1.63 (m, 2H, CH2 cyclohexyl), 1.86-1.89 (m, 2H, CH2 
cyclohexyl), 3.57-3.67 (m, 2H, CH2 acetyl), 3.75-3.80 (m, 4H, NHCH + OCH3 ), 4.48 (br. d, J = 
17.2 Hz, 1H, C6H4CH2), 4.72 (br. d, J = 17.2 Hz, 1H, C6H4CH2), 5.80 (s, 1H, CH), 5.97 (br. d, J 
= 5.6 1H, NH), 6.67 (d, J = 8.0 Hz, 2H, ArH), 6.74 (d, J = 8.0 Hz, 2H, ArH), 6.90 (d, J = 8.0 Hz, 
2H, ArH), 6.97 (d, J = 7.6 Hz, 2H, ArH), 7.10-7.14 (m, 2H, ArH), 7.32 (s, 1H, ArH)  ppm. 
13C NMR (100.6 MHz, CDCl3): δ = 24.66 (CH2), 24.74 (2CH2), 25.36 (CH2), 27.58 [C(CH3)3], 32.47 
(CH2), 40.30 (CH2C6H4), 48.97 (CH cyclohexyl), 55.19 (OCH3), 60.41 (C6H4CH2), 83.98 [C(CH3)3], 
84.01 [C(CH3)3],  114.03 (2CH), 114.09 (CH), 115.71 (2CH), 123.18 (CH), 124.87 (CH), 125.59 
(C), 127.50 (CH), 127.61 (CH), 127.77 (CH), 128.73 (C), 130.03 (2CH), 133.46 (C), 142.47 (C), 
150.45 (C), 155.37 (C), 158.74 (C), 168.23 (2C=O), 173.79 (2C=O) ppm. 
Synthesis of the cyclohexylamide of N-p-coumaroyl, N-(4-methoxybenzylamino)-[4-(O-tert-
butyloxycarbonyl), 3-methoxyphenyl]glycine, 5b’ 
Procedure B was followed using tert-butyl (4-formyl-2-methoxyphenyl) carbonate and p-coumaric 
acid to give the Ugi adduct 5b’ (0.53 g, 83%) as a white solid (from ethyl acetate/petroleum ether). 
M.p. 131.0-133.0 °C. 
1H NMR (400 MHz, CDCl3): δ = 1.08-1.13 (m, 3H, CH2 cyclohexyl), 1.24-1.33 (m, 3H, CH2 
cyclohexyl), 1.54 [s, 9H, C(CH3)3], 1.56-1.64 (m, 2H, CH2 cyclohexyl), 1.76-1.90 (m, 2H, CH2 
cyclohexyl), 3.64-3.81 (m, 7H, NHCH + 2OCH3), 4.43 (br. d, J = 17.2 Hz, 1H, C6H4CH2), 4.67 (br. 
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d, J = 17.2 Hz, 1H, C6H4CH2), 5.76 (s, 1H, NH), 5.99 (br. s, 1H, αCH), 6.42 (d, J = 15.2 Hz, 1H, 
Ar-CH=CH), 6.67 (d, J = 8.4 Hz, 2H, ArH), 6.73-6.91 (m, 5H, ArH), 7.00 (d, J = 7.6 Hz, 2H, ArH), 
7.14 (d, J = 8.0 Hz, 2H, ArH), 7.59 (d, J = 15.2 Hz, 1H, Ar-CH=CH) ppm. 
13C NMR (100.6 MHz, CDCl3): δ = 24.15 (CH2), 24.63 (CH2), 24.71 (CH2), 25.36 (CH2), 27.57 
[C(CH3)3], 32.53 (CH2), 49.00 (CH cyclohexyl), 55.18 (OCH3), 55.84 (OCH3), 60.41 (C6H4CH2), 
83.59 [C(CH3)3], 113.85 (2CH), 114.15 (CH), 114.39 (CH), 116.07 (CH), 116.17 (2CH), 122.07 
(CH), 122.50 (CH), 126.63 (C), 127.60 (2CH), 129.85 (2CH), 133.37 (C), 140.27 (C), 144.21 
(CH), 155.11 (C), 158.60 (C), 158.80 (C), 158.90 (C), 168.71 (C=O), 169.41 (C=O), 171.22 
(C=O) ppm. 
Synthesis of the cyclohexylamide of N-(protocatechoyl), N-(4-metoxybenzylamino)-[4-(O-tert-
butyloxycarbonyl)]glycine, 6a' 
Procedure B was followed using tert-butyl (4-formylphenyl) carbonate and protocatechuic acid 
to give the Ugi adduct 6a’ in quantitative yield as a colourless oil that solidified on standing. M.p. 
119.0-120.0 °C. 
1H NMR (400 MHz, CDCl3): δ = 1.03-1.86 (m, 10H, CH2 cyclohexyl), 1.57 [s, 9H, C(CH3)3], 3.72-
3.75 (m, 4H, OCH3 + CH cyclohexyl), 4.39 (br. s, 1H, C6H4CH2), 4.76 (br. s, 1H, C6H4CH2), 5.16 
(br. s, 1H, CH), 5.81 (br. s, 1H, NH), 6.72-6.79 (m, 3H, ArH), 6.89 (br. d, J = 8.4 Hz, 1H, ArH), 
7.00-7.02 (m, 2H, ArH), 7.10-7.12 (m, 3H, ArH), 7.32 (br. d, J = 8.4 Hz, 2H, ArH) ppm.  
13C NMR (100.6 MHz, CD3OCD3): δ = 24.60 (CH2), 24.66 (CH2), 25.32 (CH2), 27.67 [C(CH3)3], 
32.46 (2CH2), 48.94 (CH cyclohexyl), 55.21 (OCH3), 60.40 (CH), 83.89 [C(CH3)3], 113.96 (3CH), 
114.86 (CH), 115.05 (CH), 119.67 (CH), 121.70 (3CH), 126.75 (C), 128.68 (CH), 130.03 (C), 
130.60 (CH), 132.22 (C), 144.34 (C), 147.07 (C), 151.18 (C), 151.55 (C), 158.87 (C=O), 168.84 
(C=O), 171.18 (C=O) ppm.  
HRMS (ESI): m/z [M + H]+ calcd for C34H41N2O8: 605.2863; found: 605.2856. 
Synthesis of the cyclohexylamide of N-(protocatechoyl), N-(4-metoxybenzylamino)-[4-(O-tert-
butyloxycarbonyl), 3-methoxyphenyl]glycine, 6b' 
Procedure B was followed using tert-butyl (4-formyl-2-methoxyphenyl) carbonate and 
protocatechuic acid to give the Ugi adduct 6b' in quantitative yield as a white solid. M.p. 158.0-
159.0 °C.  
1H NMR (400 MHz, CDCl3): δ = 1.04-1.86 (m, 10H, CH2 cyclohexyl), 1.56 [s, 9H, C(CH3)3], 3.72-
3.74 (m, 7H, 2OCH3 + CH cyclohexyl), 4.42 (br. s, 1H, C6H4CH2), 4.73 (br. s, 1H, C6H4CH2), 5.10 
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(br. s, 1H, CH), 5.90 (br. s, 1H, NH), 6.73 (d, J = 8.0 Hz, 2H, ArH), 6.77 (br. d, J = 8.0 Hz, 2H, 
ArH), 6.87-6.88 (m, 3H, ArH), 6.99 (br. d, J = 8.0 Hz, 2H, ArH), 7.04 (d, J = 8.0 Hz, 2H, ArH), 
7.10 (br. s, 1H, ArH) ppm. 
13C NMR (100.6 MHz, CD3OCD3): δ = 24.59 (CH2), 24.66 (CH2), 25.33 (CH2), 27.60 [C(CH3)3], 
32.46 (2CH2), 48.89 (CH cyclohexyl), 55.20 (OCH3), 55.90 (OCH3), 60.39 (C6H4CH2), 83.70 
[C(CH3)3], 113.91 (3CH), 114.75 (CH), 115.06 (CH), 119.55 (CH), 121.87 (3CH), 122.70 (CH), 
126.93 (C), 128.69 (CH), 133.58 (C), 140.33 (C), 144.41 (C), 146.99 (C), 151.28 (C), 151.36 
(C), 158.84 (C=O), 168.75 (C=O), 173.77 (C=O)  ppm. 
HRMS (ESI): m/z [M + H]+ calcd for C35H43N2O9: 635.29686; found: 635.29800. 
Synthesis of the cyclohexylamide of N-(3,4-dihydroxyphenyl)acetyl, N-(4-methoxybenzylamino)-[4-
(O-tert-butyloxycarbonyl), 3-methoxyphenyl]glycine, 7b' 
Procedure B was followed using tert-butyl (4-formyl-2-methoxyphenyl) carbonate and 3,4-
dihydroxyphenylacetic acid to give the Ugi addcut 7b’ (0.61g, 93%) as a white solid (from ethyl 
acetate/petroleum ether). M.p. 149.0-152.0 °C. 
1H NMR (400 MHz, CDCl3): δ = 1.06-1.82 (m, 10H, CH2 cyclohexyl), 1.54 [s, 9H, C(CH3)3], 3.57-
3.66 (m, 5H, OCH3 + CH2CO), 3.69-3.78 (m, 4H, NHCH + OCH3), 4.44 (br. d, J = 16.0 Hz, 1H, 
C6H4CH2), 4.71 (br. d, J = 16.0 Hz, 1H, C6H4CH2), 5.48 (br. s, 1H, NH), 5.67 (br. s, 1H, αCH), 
6.51 (br. d, J = 7.2 Hz, 1H, H), 6.71-6.79 (m, 5H, ArH), 6.83-7.01 (m, 5H, ArH) ppm. 
13C NMR (100.6 MHz, CDCl3): δ = 24.24 (CH2), 24.68 (CH2), 24.74 (CH2), 25.33 (CH2), 27.57 
[C(CH3)3], 32.50 (CH2), 40.63 (CH2C6H3), 48.92 (CH cyclohexyl), 55.22 (OCH3), 55.88 (OCH3), 
60.39 (C6H4CH2), 83.75 [C(CH3)3], 114.00 (2CH), 114.16 (CH), 115.26 (CH), 115.75 (CH), 
120.96 (CH), 121.99 (CH), 122.52 (CH), 125.94 (C), 127.60 (CH), 127.83 (CH), 128.72 (C), 
133.45 (C), 140.24 (C), 143.70 (C), 144.37 (C), 151.23 (C), 151.34 (C), 158.80 (C=O), 168.65 
(C=O), 174.12 (C=O)  ppm. 
Synthesis of the cyclohexylamide of N-(3,4-dihydroxyphenyl)acetyl, N-(4-metoxybenzylamino)-[3,4-
(O-di-tert-butyloxycarbonyl)phenyl]glycine, 7c' 
Procedure B was followed using di-tert-butyl (4-formyl-1,2-phenylene) dicarbonate and 3,4-
dihydroxyphenylacetic acid to give the Ugi adduct 7c’ (0.63g, 86%) as a light yellow solid. M.p. 
109.0-110.0 ºC 
1H NMR (400 MHz, CDCl3): δ = 1.08-1.86 (m, 10H, CH2 cyclohexyl), 1.56 [s, 18H, 2C(CH3)3], 3.63-
3.82 (m, 6H, OCH3 + CH2CO + NHCH), 4.36 (br. d, J = 16.4 Hz, 1H, C6H4CH2), 4.68 (br. d, J = 
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16.4 Hz, 1H, C6H4CH2), 5.53 (br. s, 1H, CH), 5.95 (br. s, 1H, NH), 6.50 (br. d, J = 7.2 Hz, 1H, 
ArH), 6.68-6.88 (m, 5H, ArH), 6.94-7.48 (m, 5H, ArH + NH) ppm. 
13C NMR (100.6 MHz, CDCl3): δ = 24.24 (CH2), 24.65 (CH2), 25.36 (CH2), 27.62 [C(CH3)3], 29.69 
(CH2), 32.49 (CH2), 40.88 (CH2C6H3), 49.04 (CH cyclohexyl), 55.24 (OCH3), 63.81 (C6H4CH2), 84.19 
[C(CH3)3], 84.41 [C(CH3)3], 114.14 (2CH), 114.29 (CH), 115.20 (CH), 115.86 (CH), 121.04 (CH), 
123.21 (CH), 123.29 (CH), 123.54 (C), 124.84 (CH), 126.02 (C), 127.98 (CH), 128.21 (CH), 
142.56 (C), 143.14 (C), 143.61 (C), 144.13 (C), 150.55 (C), 150.79 (C), 158.97 (C=O), 167.94 
(C=O), 173.15 (C=O), 173.56 (C=O)  ppm.  
Synthesis of the cyclohexylamide of N-benzyloxycarbonylglycyl, N-(4-metoxybenzylamino)-[3,4-(O-
di-tert-butyloxycarbonyl)phenyl]glycine, 9c' 
Procedure B was followed using 3,4-di(O-tert-butyloxycarbonyl)benzaldehyde and N-
benzyloxycarbonylglycine to give compound 9c’ (1.12g, 94%) as a light pink solid (from ethyl 
acetate/petroleum ether). M.p. 113.0-114.0 °C. 
1H NMR (400 MHz, CDCl3): δ = 1.10-1.12 (m, 3H, CH2 cyclohexyl), 1.31-1.34 (m, 3H, CH2 
cyclohexyl), 1.56 [s, 18H, 2C(CH3)3], 1.65-1.70 (m, 2H, CH2 cyclohexyl), 1.84-1.88 (m, 2H, CH2 
cyclohexyl), 3.74-3.80 (m, 4H, OCH3 + CH cyclohexyl), 3.93 (br. d, J = 16.8 Hz, 1H, CH2), 4.10 
(br. d, J = 16.8 Hz, 1H, CH2), 4.43 (br. d, J = 17.2 Hz, 1H, ArCH2), 4.60 (br. d, J = 17.2 Hz, 1H, 
ArCH2), 5.10 (s, 2H, CH2 Z), 5.66 (d, J = 7.6 Hz, 1H, CH), 5.71-5.73 (m, 2H, 2NH), 6.75 (d, J = 
8.4 Hz, 2H, ArH), 6.94 (d, J = 8.4 Hz, 2H, ArH), 7.15 (s, 2H, ArH), 7.30-7.35 (m, 6H, ArH) ppm. 
13C NMR (100 6 MHz, CDCl3): δ = 22.66 (CH2), 24.73 (CH2), 24.81 (CH2), 25.40 (CH2), 27.58 
[2C(CH3)3], 29.63 (CH2), 32.65 (CH2), 43.46 (CH2),  48.91 (CH cyclohexyl), 49.27 (ArCH2), 55.17 
(OCH3), 62.75 (CH), 66.85 (CH2 Z), 84.03 [2C(CH3)3], 114.17 (CH), 123.37 (CH), 125.00 (CH), 
127.69 (CH), 127.95 (2CH), 128.03 (2CH), 128.46 (3CH), 133.04 (C), 136.39 (C), 142.59 (C), 
142.75 (C), 150.39 (C), 150.43 (C), 156.14 (C=O), 158.91 (2C=O), 167.37 (C=O), 170.12 (C=O) 
ppm. 
HRMS (ESI): m/z [M + H]+ calcd for C42H54N3O11: 776.37583; found: 776.37679. 
 
4.4.1.3. Synthesis of the cyclohexylamides of N-acyl (hydroxyphenyl)glycine  
Synthesis of the cyclohexylamide of N-benzoyl, (4-hydroxyphenyl)glycine, 1a 
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Procedure B was followed using Ugi adduct 1a' to give compound 1a (0.12 g, 34%) as a white 
solid (from diethyl ether). Alternatively, procedure C using tert-butyl (4-formylphenyl) carbonate and 
benzoic acid was followed to give comound 1a (0.22g,  62%). M.p. 141.0-142.0 °C. 
1H NMR (400 MHz, CD3OCD3): δ = 1.14-1.36 (m, 5H, CH2 cyclohexyl), 1.57-2.12 (m, 5H, CH2 
cyclohexyl), 3.68-3.76 (m, 1H, CH cyclohexyl), 5.64 (s, 1H, CH), 6.82 (d, J = 8.4 Hz, 2H, ArH), 
7.37 (d, J = 8.4 Hz, 2H, ArH), 7.46-7.50 (m, 2H, ArH), 7.53-7.57 (m, 1H, ArH), 7.93-7.95 (m, 
2H, ArH) ppm. 
13C NMR (100.6 MHz, CD3OCD3): δ = 25.48 (CH2), 25.57 (CH2), 26.22 (CH2), 33.21 (CH2), 33.30 
(CH2), 49.10 (CH cyclohexyl), 57.27 (CH), 115.91 (2CH), 128.08 (2CH), 129.17 (2CH), 129.58 
(2H), 131.04 (C), 132.13 (CH), 135.40 (C), 157.83 (C), 166.36 (C=O), 170.12 (C=O) ppm. 
HRMS (ESI): m/z [M + H]+ calcd for C21H25N2O3: 353.1865; found: 353.1856. 
Synthesis of the cyclohexylamide of N-benzoyl, (4-hydroxy-3-methoxyphenyl)glycine, 1b 
Procedure C was followed using tert-butyl (4-formyl-2-methoxyphenyl) carbonate and benzoic 
acid to give compound 1b (0.29g, 76%) as a light yellow solid (from diethyl ether). M.p. 169.0-
170.0 °C. 
1H NMR (400 MHz, CD3OCD3): δ = 1.15-1.36 (m, 5H, CH2 cyclohexyl), 1.57-1.91 (m, 5H, CH2 
cyclohexyl), 3.69-3.75 (m, 1H, CH cyclohexyl), 3.83 (s, 3H, OCH3), 5.67 (s, 1H, CH), 6.81 (d, J 
= 8.0 Hz, 1H, ArH), 7.01 (dd, J = 8.0 Hz, J = 2.0 Hz, 1H, ArH), 7.19 (d, J = 2.0 Hz, 1H, ArH), 
7.46-7.57 (m, 3H, ArH), 7.94-7.96 (m, 2H, ArH), 8.04 (s, 1H, NH) ppm. 
13C NMR (100.6 MHz, CD3OCD3): δ = 25.48 (CH2), 25.56 (CH2), 26.22 (CH2), 33.21 (CH2), 33.29 
(CH2), 49.09 (CH cyclohexyl), 56.23 (CH3), 57.60 (CH), 111.94 (CH), 115.53 (CH), 121.15 (CH), 
128.12 (2CH), 129.16 (2CH), 131.49 (C), 132.13 (CH), 135.43 (C), 147.05 (C), 148.17 (C), 
166.46 (C=O), 170.07 (C=O) ppm. 
HRMS (ESI): m/z [M + H]+ calcd for C22H27N2O4: 383.1971; found: 383.1973. 
Synthesis of the cyclohexylamide of N-benzoyl, (3,4-dihydroxyphenyl)glycine, 1c 
Procedure C was followed using di-tert-butyl (4-formyl-1,2-phenylene) dicarbonate and benzoic 
acid. The residue obtained after removal of TFA was chromatographed through silica using ethyl 
acetate/petroleum ether as eluent to give compound 1c (0.24g, 66%) as a white solid. M.p. 127.0-
128.0 °C. 
1H NMR (400 MHz, CD3OCD3): δ = 1.28-1.36 (m, 5H, CH2 cyclohexyl), 1.57-1.92 (m, 5H, CH2 
cyclohexyl), 3.69-3.77 (m, 1H, CH cyclohexyl), 5.59 (d, J = 7.6 Hz, 1H, CH), 6.80 (d, J = 8.4 
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Hz, 1H, ArH), 6.88 (dd, J = 8.4 Hz, J = 2.0 Hz, 1H, ArH), 7.04 (d, J = 2.0 Hz, 1H, ArH), 7.33 (d, 
J = 7.6 Hz, 1H, C6H5CONH), 7.46-7.55 (m, 3H, ArH), 7.90-7.97 (m, 5H, 2ArH + 2OH + NHC6H11) 
ppm. 
13C NMR (100.6 MHz, CD3OCD3): δ = 25.49 (CH2), 25.57 (CH2), 26.22 (CH2), 33.24 (CH2), 33.32 
(CH2), 49.23 (CH cyclohexyl), 57.53 (CH), 115.58 (CH), 115.91 (CH), 119.97 (CH), 128.07 
(2CH), 129.17 (2CH), 131.73 (C), 132.12 (CH), 135.42 (C), 145.66 (C), 145.77 (C), 166.39 
(C=O), 170.17 (C=O) ppm. 
HRMS (ESI): m/z [M + H]+ calcd for C21H25N2O4: 369.1814; found: 369.1811. 
Synthesis of the cyclohexylamide of N-acetyl, (4-hydroxyphenyl)glycine, 2a 
Procedure B was followed using Ugi adduct 2a' to give compound 2a as a white solid 
(from acetone). M.p. 241.0-242.0 °C. 
1H NMR (400 MHz, DMSO): δ = 1.16-1.24 (m, 5H, CH2 cyclohexyl), 1.49-1.75 (m, 5H, CH2 
cyclohexyl), 1.85 (s, 3H, CH3CO), 3.40-3.45 (m, 1H, NHCH), 5.31 (d, J = 8.4 Hz, 1H, CH), 6.66 
(d, J = 8.4 Hz, 2H, ArH), 7.15 (d, J = 8.4 Hz, 2H, ArH), 7.99 (d, J = 8.0 Hz, 1H, NH), 8.29 (d, J 
= 8.4 Hz, 1H, NH), 9.34 (s, 1H, OH) ppm. 
13C NMR (100.6 MHz, DMSO): δ = 22.46 (CH3), 24.37 (CH2), 24.49 (CH2), 25.17 (CH2), 32.18 
(CH2), 32.30 (CH2), 47.52 (CH cyclohexyl), 55.38 (CH), 114.88 (2CH), 128.11 (2CH), 129.62 
(C), 156.59 (C), 168.69 (C=O), 169.29 (C=O) ppm. 
HRMS (ESI): m/z [M + H]+ calcd for C16H23N2O3: 291.1709; found: 291.1705. 
Synthesis of the cyclohexylamide of N-(2-Naphthyl)acetyl, (3,4-dihydroxyphenyl)glycine, 3c 
Procedure C was followed using di-tert-butyl (4-formyl-1,2-phenylene) dicarbonate and 2-
naphthylacetic acid. The residue obtained after removal of TFA was dissolved in ethyl acetate (100 
cm3) and washed with KHSO4 (1 mol.dm-3), NaHCO3 (1 mol.dm-3) and brine (3 times 25 cm3 each). 
The organic layer was dried with MgSO4 and the solvent evaporated at reduced pressure to give 
compound 3c (0.34g, 78%) as a light yellow solid (from ethyl acetate/dichloromethane). M.p. 
220.0-221.0 °C. 
1H NMR (400 MHz, CD3OCD3): δ = 1.06-1.33 (m, 5H, CH2 cyclohexyl), 1.63-1.83 (m, 5H, CH2 
cyclohexyl), 3.59-3.66 (m, 1H, CH cyclohexyl), 3.81 [d, J = 2.8 Hz, CH2 (2-naphthyl)acetyl], 5.38 
(d, J = 8.0 Hz, 1H, CH), 6.75 (s, 2H, ArH), 6.95 (s, 1H, ArH), 7.17 (d, J = 8.0 Hz, 1H, C6H3CONH), 
7.46-7.53 (m, 3H, ArH), 7.70 (d, J = 7.6 Hz, 1H, NHC6H11), 7.84-7.89 (m, 6H, ArH + 2OH) ppm. 
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13C NMR (100.6 MHz, CD3OCD3): δ = 25.42 (CH2), 25.52 (CH2), 26.18 (CH2), 33.19 (CH2), 33.28 
(CH2), 43.57 [CH2 (2-naphthyl)acetyl], 49.01 (CH cyclohexyl), 57.28 (CH), 115.46 (CH), 115.84 
(CH), 119.79 (CH), 126.32 (CH), 126.80 (CH), 128.40 (2CH), 128.54 (CH), 128.59 (CH), 128.65 
(CH), 131.80 (C), 133.29 (C), 134.49 (C), 134.85 (C), 145.57 (C), 145.74 (C), 170.04 (C=O), 
170.25 (C=O) ppm. 
HRMS (ESI): m/z [M + H]+ calcd for C26H29N2O4: 433.2127; found: 433.2131. 
Synthesis of the cyclohexylamide of N-(4-hydroxyphenyl)acetyl, (4-hydroxy, 3-
methoxyphenyl)glycine,  4b 
Procedure B was followed using Ugi adduct 4b’ to give compound 4b (0.53g, 59%) as a light 
pale solid (from ethyl acetate/petroleum ether). M.p. 165.0-167.0 °C. 
1H NMR (400 MHz, CD3OCD3): δ = 1.23-1.31 (m, 5H, CH2 cyclohexyl), 1.56-1.72 (m, 4H, CH2 
cyclohexyl), 1.81-1.85 (m, 1H, CH2 cyclohexyl), 3.52 (t, J = 2.8 Hz,  2H, CH2 acetyl), 3.56-3.66 
(m, 1H, CH cyclohexyl), 3.76 (s, 3H, OCH3), 5.43 (s, 1H, αCH), 6.75 (d, J = 8.0 Hz, 2H, ArH), 
6.79 (d, J = 8.0 Hz, 2H, ArH), 6.84 (dd, J = 2.0 Hz, J = 0.4 Hz, 1H, ArH), 6.87 (dd, J = 2.0 Hz, J 
= 0.4 Hz,  1H, ArH), 6.99 (d, J = 2.0 Hz,  1H, ArH), 7.19 (d, J = 8.4 Hz, 1H ArH) ppm. 13C NMR 
(100.6 MHz, CD3OCD3): δ = 25.43 (CH2), 25.53 (CH2), 26.20 (CH2), 33.17 (CH2), 33.25 (CH2), 
42.70 (CH2 acetyl), 48.92 (CH cyclohexyl), 56.13 (OCH3), 57.04 (αCH), 111.46 (CH), 115.44 
(CH), 115.96 (2CH), 120.62 (CH), 127.70 (C), 131.08 (2CH), 131.62 (C), 146.85 (C), 148.06 
(C), 157.02 (C), 169.97 (C=O), 170.85 (C=O) ppm.  
Synthesis of the cyclohexylamide of N-(4-hydroxyphenyl)acetyl, (3,4-dihydroxyphenyl)glycine, 4c 
Procedure B was followed using Ugi adduct 4c’ (0.359 g, 0.500 mmol). The residue obtained 
was chromatographed through silica using ethyl acetate/petroleum ether as eluent to give 
compound 4c (0,16 g, 80.2%) as a light orange oil. 
1H NMR (400 MHz, CD3OCD3): δ = 1.24-1.32 (m, 5H, CH2 cyclohexyl), 1.54-1.72 (m, 4H, CH2 
cyclohexyl), 1.81-1.83 (m, 1H, CH2 cyclohexyl), 3.52 (s, 2H, CH2 acetyl), 3.60-3.78 (m, 1H, CH 
cyclohexyl), 5.39 (d, J = 7.6 Hz, 1H, CH), 6.75-6.80 (m, 4H, ArH), 6.94 (s, 1H, ArH), 7.16 (d, J 
= 8.4 Hz, 2H, ArH), 7.32 (br. d, J = 8.0 Hz,  1H, NH), 7.63 (d, J = 7.6 Hz, 1H, NH) ppm. 
13C NMR (100.6 MHz, CD3OCD3): δ = 25.41 (CH2), 25.51 (CH2), 26.16 (CH2), 33.14 (CH2), 33.21 
(CH2), 42.62 (CH2 acetyl), 49.11 (CH cyclohexyl), 57.23 (CH), 115.34 (CH), 115.83 (CH), 
116.06 (2CH), 119.98 (CH), 127.47 (C), 131.10 (2CH), 131.53 (C), 145.58 (C), 145.74 (C), 
157.08 (C), 170.28 (C=O), 171.30 (C=O) ppm. 
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Synthesis of the cyclohexylamide of N-protocatechoyl, (4-hydroxyphenyl)glycine, 6a  
Procedure B was followed using Ugi adduct 6a’ (0,454 g, 0.750 mmol). The residue obtained 
after removal of TFA was dissolved in ethyl acetate (100 cm3) and washed with KHSO4 (1 mol.dm-
3), NaHCO3 (1 mol.dm-3) and brine (3 times 25 cm3 each). The organic layer was dried with MgSO4 
and the solvent evaporated at reduced pressure to give compound 6a (0.21 g, 72%) as a white 
solid (from ethyl acetate/dichloromethane).  M.p. 158.0-159.0 °C. 
1H NMR (400 MHz, CD3OCD3): δ = 1.11-1.39 (m, 5H, CH2 cyclohexyl), 1.57-1.78 (m, 4H, CH2 
cyclohexyl), 1.87-1.90 (m, 1H, CH2 cyclohexyl), 3.69-3.75 (m, 1H, CH cyclohexyl), 5.60 (d, J = 7.6 
Hz, 1H, CH), 6.80-6.82 (m, 2H, ArH), 6.89 (d, J = 8.0 Hz, 1H, ArH), 7.34-7.36 (m, 3H, ArH), 
7.46 (d, J = 2.0 Hz, 1H, ArH), 7.75 (d, J = 7.6 Hz, 1H, NH), 8.42 (br. s, 3H, OH) ppm. 
13C NMR (100.6 MHz, CD3OCD3): δ = 25.48 (CH2), 25.56 (CH2), 26.21 (CH2), 33.22 (CH2), 33.29 
(CH2), 49.21 (CH cyclohexyl), 57.29 (CH), 115.50 (CH), 115.61 (CH), 115.92 (2CH), 120.38 
(CH), 127.16 (C), 129.53 (2CH), 131.30 (C), 145.60 (C), 149.20 (C), 157.79 (C), 166.23 (C=O), 
170.41 (C=O) ppm. 
HRMS (ESI): m/z [M + H]+ calcd for C21H25N2O5: 385.17635; found: 385.16979. 
Synthesis of the cyclohexylamide of N-protocatechoyl, (4-hydroxy-3-methoxyphenyl)glycine, 6b 
Procedure B was followed using Ugi adduct 6b’ (0,636 g, 1.000 mmol). The residue obtained 
after removal of TFA was dissolved in ethyl acetate (100 cm3) and washed with KHSO4 (1 mol.dm-
3), NaHCO3 (1 mol.dm-3) and brine (3 times 25 cm3 each). The organic layer was dried with MgSO4 
and the solvent evaporated at reduced pressure to give to give compound 6b (0.28 g, 67.5%) as a 
white solid (from ethyl acetate/dichloromethane).  M.p. 129.0-130.0 °C. 
1H NMR (400 MHz, CD3OCD3): δ = 1.17-1.35 (m, 5H, CH2 cyclohexyl), 1.58-1.89 (m, 5H, CH2 
cyclohexyl), 3.68-3.73 (m, 1H, CH cyclohexyl), 3.81 (s, 3H, OCH3), 5.63 (d, J = 7.2 Hz, 1H, CH), 
6.80 (d, J = 8.0 Hz, 1H, ArH), 6.89 (d, J = 8.4 Hz, 1H, ArH), 6.99 (dd, J = 8.4 Hz,  J = 2.0 Hz, 
1H, ArH), 7.17 (d, J = 2.0 Hz, 1H, ArH), 7.36 (dd, J = 8.4,  J = 2.0 Hz, 1H, ArH), 7.40 (br. s., 1H, 
NH), 7.48 (d, J = 2.0 Hz, 1H, ArH), 7.81 (d, J = 7.2 Hz, 1H, NH) ppm. 
13C NMR (100.6 MHz, CD3OCD3): δ = 25.48 (CH2), 25.56 (CH2), 26.21 (CH2), 33.24 (CH2), 33.30 
(CH2), 49.20 (CH cyclohexyl), 56.22 (CH3), 57.66 (CH), 111.91 (CH), 115.58 (2CH), 115.62 
(CH), 120.44 (CH), 121.07 (CH), 127.15 (C), 131.70 (C), 145.63 (C), 147.05 (C), 148.16 (C), 
149.25 (C), 166.41 (C=O), 170.39 (C=O) ppm. 
HRMS (ESI): m/z [M + H]+ calcd for C22H27N2O6: 415.18691; found: 415.18636. 
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Synthesis of the cyclohexylamide of N-protocatechoyl, (3,4-dihydroxyphenyl)glycine, 6c 
Procedure C was followed using di-tert-butyl (4-formyl-1,2-phenylene) dicarbonate and 
protocatechuic acid. The residue obtained after removal of TFA was chromatographed through 
silica using ethyl acetate/petroleum ether as eluent to give compound 6c (0.29 g, 69%) as a white 
solid (from ethyl acetate/dichloromethane). M.p. 177.0-178.0 °C. 
1H NMR (400 MHz, CD3OCD3): δ = 1.21-1.33 (m, 6H, CH2 cyclohexyl), 1.57-1.91 (m, 4H, CH2 
cyclohexyl), 3.71-3.74 (m, 1H, CH cyclohexyl), 5.55 (d, J = 7.6 Hz, 1H, CH), 6.78 (d, J = 8.0 
Hz, 1H, ArH), 6.85 (dd, J = 8.4 Hz, J = 2.0 Hz, 1H, ArH), 6.90 (d, J = 8.0 Hz, 1H, ArH), 7.03 (d, 
J = 2.0 Hz, 1H, ArH), 7.35 (dd, J = 8.4 Hz, J = 2.0 Hz, 1H, ArH), 7.48 (d, J = 2.0 Hz, 1H, ArH),  
7.72 (d, J = 7.2 Hz, 1H, C6H3CONH), 7.95 (br. s, 1H, OH), 8.08 (br. s, 1H, OH), 8.45 (br. s, 1H, 
OH), 8.49 (br. s, 1H, OH) ppm. 
13C NMR (100.6 MHz, CD3OCD3): δ = 25.49 (CH2), 25.57 (CH2), 26.23 (CH2), 33.21 (CH2), 33.27 
(CH2), 49.23 (CH cyclohexyl), 57.35 (CH), 115.54 (CH), 115.86 (CH), 119.84 (2CH), 120.36 
(2CH), 127.07 (C), 127.10 (C), 131.91 (C), 131.94 (C), 145.65 (C), 149.26 (C), 166.17 (C=O), 
170.34 (C=O) ppm. 
HRMS (ESI): m/z [M + Na]+ calcd for C21H24N2NaO6: 423.1532; found: 423.1528. 
Synthesis of the cyclohexylamide of N-(3,4-dihydroxyphenyl)acetyl, (4-hydroxy, 3-
methoxyphenyl)glycine, 7b 
Procedure B was followed using Ugi adduct 7b’ (0.324 g, 0.500 mmol). The residue obtained 
was chromatographed through silica using ethyl acetate/petroleum ether as eluent to give 
compound 7b (0.095 g, 44%) as a white solid (from ethyl acetate/petroleum ether). M.p. 150.0-
152.0 °C. 
1H NMR (400 MHz, CD3OCD3): δ = 1.21-1.35 (m, 5H, CH2 cyclohexyl), 1.57-1.85 (m, 5H, CH2 
cyclohexyl), 3.45 (s, 2H, CH2 acetyl), 3.63-3.65 (m, 1H, CH cyclohexyl), 3.71 (s, 3H, OCH3), 5.34 
(br. s, 1H, αCH), 6.69 (dd, J = 8.0 Hz, J = 2.0 Hz, 1H, ArH), 6.74-6.88 (m, 3H, ArH), 6.96 (s, 1H, 
ArH), 7.04 (d, J = 8.8 Hz, 1H, ArH), 7.23 (br. s, 2H, OH), 7.47 (br. s, 1H, OH), 7.56 (d, J = 9.6 
Hz, 1H, ArH) ppm. 
13C NMR (100.6 MHz, CD3OCD3): δ = 25.43 (CH2), 25.53 (CH2), 26.19 (CH2), 33.18 (CH2), 33.27 
(CH2), 40.67 (CH2C6H3), 49.02 (CH cyclohexyl), 56.22 (CH3), 56.16 (αCH), 111.42 (CH), 114.48 
(CH), 115.54 (CH), 116.01 (CH), 117.15 (CH), 118.12 (CH), 118.57 (CH), 120.65 (CH), 121.42 
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(CH), 126.13 (C), 128.44 (C), 130.61 (CH),  131.65 (C), 132.54 (C), 133.81 (C), 144.21 (C), 
144.88 (C), 145.90 (C), 146.99 (C), 148.16 (C), 158.87 (C), 170.04 (C=O), 170.83 (C=O) ppm. 
Synthesis of the cyclohexylamide of N-(3,4-dihydroxyphenyl)acetyl, (3,4-dihydroxyphenyl)glycine, 
7c 
Procedure B was followed using Ugi adduct 7c’ (0,367 g, 0.500 mmol). The residue obtained 
was chromatographed through silica using ethyl acetate/petroleum ether as eluent to give 
compound 7c (0.131 g, 63.4%) as a brown solid. M.p. 115.0-116.0 ºC. 
1H NMR (400 MHz, CD3OCD3): δ = 1.24-1.34 (m, 5H, CH2 cyclohexyl), 1.59-1.72 (m, 4H, CH2 
cyclohexyl), 1.81-1.88 (m, 1H, CH2 cyclohexyl), 3.46 (s, 2H, CH2 acetyl), 3.63-3.80 (m, 1H, CH 
cyclohexyl), 5.33 (d, J = 7.6 Hz, 1H, CH), 6.67 (dd, J = 8.0 Hz, J = 2.0 Hz, 1H, ArH), 6.71-6.83 
(m, 4H, ArH), 6.87 (d, J = 2.0 Hz, 1H, ArH), 6.91 (d, J = 1.2 Hz, 1H, ArH), 7.22 (br. d, J = 7.6 
Hz,  1H, NH), 7.50 (d, J = 7.6 Hz, 1H, NH), 8.06 (s, 1H, OH) ppm. 
13C NMR (100.6 MHz, CD3OCD3): δ = 25.43 (CH2), 25.53 (CH2), 26.19 (CH2), 33.17 (CH2), 33.25 
(CH2), 42.95 (CH2 acetyl), 49.08 (CH cyclohexyl), 57.24 (CH), 115.36 (CH), 115.90 (CH), 
117.17 (CH), 119.69 (CH), 121.47 (CH), 128.26 (C), 130.63 (CH), 131.60 (C), 144.81 (C), 
145.54 (C), 145.69 (C), 145.80 (C), 170.16 (C=O), 171.08 (C=O) ppm. 
Synthesis of the cyclohexylamide of N-hydrocaffeoyl, (3,4-dihydroxyphenyl)glycine, 8c 
Procedure C was followed using di-tert-butyl (4-formyl-1,2-phenylene) dicarbonate and 
hydrocaffeic acid. The residue obtained after removal of TFA was chromatographed through silica 
using ethyl acetate/petroleum ether as eluent to give 8c (0.32 g, 74%) as a white solid. M.p. 112.0-
113.0 °C. 
1H NMR (400 MHz, CD3OD): δ = 1.18-1.36 (m, 6H, CH2 cyclohexyl), 1.61-1.90 (m, 4H, CH2 
cyclohexyl), 2.32-2.54 (m, 2H, CH2), 2.72-2.77 (m, 2H, CH2), 3.72-3.88 (m, 1H, CH cyclohexyl), 
5.23 (s, 1H, CH), 6.54 (s, 1H, ArH), 6.64-6.68 (m, 2H, ArH), 6.74-6.68 (m, 5H, ArH), 7.02 (d, 
J = 8.4 Hz, 2H, ArH) ppm. 
13C NMR (100.6 MHz, CD3OD): δ = 26.06 (CH2), 26.12 (CH2), 26.59 (CH2), 29.27 (CH2), 33.47 
(CH2), 33.5 (CH2), 38.28 (CH2), 49.97 (CH cyclohexyl), 58.28 (CH), 114.77 (CH), 115.70 (CH), 
116.37 (CH), 117.49 (CH), 118.69 (CH), 120.23 (CH), 130.31 (C), 130.59 (CH), 131.47 (C), 
131.68 (C), 134.96 (C), 144.61 (C), 146.46 (C), 159.31 (C), 171.97 (C=O), 174.80 (C=O) ppm. 
HRMS (ESI): m/z [M + H]+ calcd for C23H29N2O6: 429.2026; found: 429.2030. 
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Synthesis of the cyclohexylamide of N-benzyloxycarbonylglycyl, (3,4-dihydroxyphenyl)glycine, 9c 
Procedure B was followed using Ugi adduct 9c' (0.58 g, 0.75 mmol) to give 9c (0.25 g, 74%) 
as a white solid (from ethyl acetate/diethyl ether). M.p. 162.0-163.0 °C. 
1H NMR (400 MHz, CD3OCD3): δ = 1.11-1.71 (m, 10H, CH2 cyclohexyl), 3.63-3.67 (m, 1H, CH 
cyclohexyl), 3.87 (d, J = 6.0 Hz, 2H, CH2), 5.10 (s, 2H, CH2 Z), 5.32 (d, J = 7.6 Hz, 1H, CH), 
6.70 (br. d, J = 7.6 Hz, 1H, NH), 6.73 (s, 2H, ArH), 6.91 (s, 1H, ArH), 7.26-7.39 (m, 6H, ArH + 
NH), 7.66 (d, J = 7.2 Hz, 1H, NH) ppm. 
13C NMR (100.6 MHz, CD3OCD3): δ = 25.62 (CH2), 26.27 (CH2), 29.26 (CH2), 33.26 (CH2), 33.38 
(CH2), 45.01 (CH2), 49.20 (CH cyclohexyl), 57.16 (CH), 66.93 (CH2 Z), 115.45 (CH), 115.90 
(CH), 119.80 (CH), 128.63 (2CH), 129.24 (3CH), 131.60 (C), 138.16 (C), 145.66 (C), 145.78 
(C), 157.63 (C=O), 169.13 (C=O), 170.00 (C=O) ppm. 
HRMS (ESI): m/z [M + H]+ calcd for C24H30N3O6: 456.2135; found: 456.2141. 
 
4.5. Synthesis of phenolic and catecholic derivatives of dehydrophenylalanine 
Procedure D: Synthesis of the phenoyl amides of N-(tert-butyloxycarbonyl) dehydrophenylalanine 
and phenylalanine. 
To a solution of N-(tert-butyloxycarbonyl) dehydrophenylalanine or phenylalanine 
in acetonitrile (0.01 mol.dm-3), 1.0 equiv. of HOBt was added, followed by 1.0 equiv. of HBTU, 1.0 
equiv. of amine and 1.1 equiv. of NEt3 in an ice bath. After stirring for 4 hours at room temperature, 
the solvent was evaporated at reduced pressure. The residue was dissolved in ethyl acetate (100 
cm3) and washed with KHSO4 (1 mol.dm-3), NaHCO3 (1.mol dm-3) and brine (3 times 25 cm3 each). 
The organic layer was dried with MgSO4 and the solvent evaporated at reduced pressure to give 
the corresponding compound. 
Procedure E: Cleavage of the amine protecting group. 
To a hydroxyphenylamide of N-(tert-butyloxycarbonyl) dehydrophenylalanine and phenylalanine, 
6 cm3 of trifluroacetic acid (TFA) were added and the solution left to stand for 30 min. The solvent 
was evaporated at reduced pressure and the residue triturated with diethyl ether and filtered to 
give the corresponding hydroxyphenylamide of dehydrophenylalanine and phenylalanine. 
Procedure F: Coupling of unprotected dehydrophenylalanine or phenylalanine derivatives with a 
phenolic acid. 
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To a solution of the hydroxyphenylamide of dehydrophenylalanine or phenylalanine 
in acetonitrile (0.0100 mol.dm-3), 1.0 equiv. of HOBt was added, followed by 1.0 equiv. of HBTU, 
1.0 equiv. of protocatechuic acid and 2.2 equiv. of NEt3 in an ice bath. After stirring overnight at 
room temperature, the solvent was evaporated at reduced pressure. The residue was dissolved in 
ethyl acetate (40 cm3) and washed with KHSO4 (1 mol.dm-3), NaHCO3 (1 mol.dm-3) and brine (3 
times 10 cm3 each). The organic layer was dried with MgSO4 and the solvent evaporated at reduced 
pressure to give the corresponding hydroxyphenylamide of N-phenoyl dehydrophenylalanine or 
phenylalanine. 
 
4.5.1. Synthesis of N-(tert-butyloxycarbonyl) dehydrophenylalanine 
Synthesis of methyl ester of N-(tert-butyloxycarbonyl) dehydrophenylalanine, Boc-Phe-OMe, 11 
To a solution of Boc-Phe(-OH)-OMe (1.48 g, 5.000 mmol) in dry acetonitrile (0.5 mol.dm-3), 
0.11 equiv. of DMAP was added followed by 1.1 equiv. of tert-butylpyrocarbonate under rapid 
stirring at room temperature. The reaction was monitored by TLC (diethyl ether/n-hexane, 1:1) 
until all the reactant had been consumed. Then 2% in volume of TMG was added, stirring was 
continued and the reaction followed by TLC. When all the reactant was consumed evaporation at 
reduced pressure gave a residue that was partitioned between 100 cm3 of ethyl acetate and 25 
cm3 of KHSO4 (1 mol.dm-3). The organic phase was washed with KHSO4 (1 mol.dm-3), NaHCO3 (1 
mol.dm-3) and brine (2 times 30 cm3 each) and dried over MgSO4. Removal of the solvent afforded 
compound 11 (1.36 g, 98%) as a white solid.90 
1HNMR (400 MHz, CDCl3): 1.40 (s, 9H, CH3 Boc), 3.86 (s, 3H, OCH3), 6.17 (s, 1H, H), 7.26 (br. 
s, 1H, NH), 7.30-7.39 (m, 3H, ArH), 7.54 (d, J = 7.2 Hz, 2H, ArH) ppm. 
 
Synthesis of N-(tert-butyloxycarbonyl) dehydrophenylalanine, Boc-Phe-OH, 12 
To a solution of compound 11 (0.69 g, 2.500 mmol.) in dioxane (0.2 mol.dm-3), 7.5 cm3 of 
NaOH (1 mol.dm-3) was added under rapid stirring at room temperature. The reaction was 
monitored by TLC. When the reaction was complete, KHSO4 was added until pH 3. The aqueous 
solution was extracted with ethyl acetate (5 times 15 cm3), the organic fractions were collected and 
washed with brine (1 time 25 cm3) and dried over MgSO4. Removal of the solvent gave compound 
12 (0.63 g, 95%) as a white solid. (from ethyl acetate/petroleum ether). M.p. 161.0-162.0 °C. 
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1HNMR (400 MHz, DMSO): δ = 1.36 (s, 9H, CH3 Boc), 7.16 (s, 1H, H), 7.31-7.41 (m, 3H, ArH), 
7.62 (d, J = 7.2 Hz, 2H, ArH), 8.46 (br. s, 1H, NH), 12.64 (br. s, 1H, OH) ppm. 
13CNMR (100.6 MHz, DMSO): δ = 28.03 [C(CH3)3], 78.89 [C(CH3)3], 127.13 (CH), 128.44 (2CH), 
129.03 (CH), 129.77 (2CH), 131.37 (C), 133.91 (C), 153.76 (C=O), 166.88 (C=O) ppm. 
HRMS (ESI): m/z [M + H]+ calcd for C14H18NO4: 264.12358; found: 264.12323. 
 
4.5.2. Synthesis of the hydroxyphenylamides of N-(tert-butyloxycarbonyl) 
dehydrophenylalanine and phenylalanine 
Synthesis of the 4-hydroxybenzylamide of N-(tert-butyloxycarbonyl) dehydrophenyalanine, Boc-
Phe-NH-Bzl(4-OH), 12a 
Procedure D was followed using compound 12 (0.62 g, 2.350 mmol) and 4-
hydroxybenzylamine to give compound 12a (0.76 g, 88%) as a yellow oil. 
1HNMR (400 MHz, DMSO): δ = 1.38 (br. s, 9H, CH3 Boc), 4.24 (d, J = 6.0 Hz, 2H, CH2 Bzl), 6.68 
(d, J = 8.4 Hz, 2H, ArH Bzl), 6.97 (br. s, 1H, NH), 7.11 (d, J = 8.4 Hz, 2H, ArH Bzl), 7.27-7.38 
(m, 4H, ArH Phe + CH), 7.53 (d, J = 7.6 Hz, 2H, ArH Phe), 8.39 (br. s, 1H, NH), 9.22 (s, 1H, 
OH) ppm. 
13C NMR (100.6 MHz, DMSO): δ = 28.03 [C(CH3)3], 42.15 (CH2 Bzl), 78.86 [C(CH3)3], 114.82 
(2CH), 128.30 (2CH), 128.36 (2CH), 128.60 (CH), 128.71 (CH), 129.29 (2CH), 129.80 (C), 
134.48 (C), 153.50 (C), 156.11 (C), 165.34 (C=O), 170.33 (C=O) ppm. m/z (HRESI-MS). 
HRMS (ESI): m/z [M + H]+ calcd for C21H25N2O4: 369.18143; found: 369.18199. 
 
 
Synthesis of the dopamide of N-(tert-butyloxycarbonyl)dehydrophenyalanine, Boc-Phe-NH-Dopa, 
12b 
Procedure D was followed using compound 12 (0.62 g, 2.350 mmol) and dopamine 
hydrochloride to give compound 12b (0.91 g, 97%) as a light yellow solid.  
1HNMR (400 MHz, CD3OCD3): δ = 1.41 (s, 9H, CH3 Boc), 2.75 (t, J = 7.6 Hz, 2H, CH2), 3.49-3.54 
(m, 2H, CH2), 6.61 (dd, J = 2.0 Hz, J = 8.0 Hz, 1H, ArH Dopa), 6.77 (d, J = 8.0 Hz, 1H, ArH 
Dopa), 6.78 (d, J = 2.0 Hz, 1H, ArH Dopa), 7.13 (s, 1H, CH), 7.31-7.49 (m, 5H, ArH Phe + 
2NH), 7.58 (d, J = 7.6 Hz, 2H, ArH), 7.72 (br. s, 1H, OH), 7.79 (br. s, 1H, OH) ppm. 
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13C NMR (100.6 MHz, CD3OCD3): δ = 28.39 [C(CH3)3], 35.88 (CH2 Dopa), 42.30 (CH2 Dopa), 80.23 
[C(CH3)3], 116.05 (CH), 116.58 (CH), 120.82 (CH), 129.12 (CH), 129.24 (2CH), 129.34 (C), 
130.21 (3CH), 132.04 (C), 135.78 (C), 144.33 (C), 145.87 (C), 154.34 (C=O), 166.05 (C=O) 
ppm. 
HRMS (ESI): m/z [M + H]+ calcd for C22H27N2O5: 399.19200; found: 399.19216. 
Synthesis of the 4-hydroxybenzylamide of N-(tert-butyloxycarbonyl) phenyalanine, Boc-Phe-NH-
Bzl(4-OH), 13a 
Procedure D was followed using compound N-(tert-butyloxycarbonyl) phenylalanine (0.66 g, 
2.500 mmol) and 4-hydroxybenzylamine to give compound 13a (0.87 g, 94%) as a white solid 
(from ethyl acetate/petroleum ether). M.p. 123.0-124.0 °C. 
1HNMR (400 MHz, DMSO): δ = 1.29 (s, 9H, CH3 Boc), 2.68-2.77 (m, 1H, CH2), 2.91-2.95 (m, 
1H, CH2), 4.14-4.19 (m, 3H, CH2 Bzl + CH), 6.44 (br. d, J = 7.6 Hz, 1H, NH), 6.66 (d, J = 8.4 
Hz, 2H, ArH Bzl), 6.89 (d, J = 8.4 Hz, 1H, ArH Phe), 6.98 (d, J = 8.0 Hz, 2H, ArH Bzl), 7.17-7.19 
(m, 1H, ArH Phe), 7.23-7.26 (m, 3H, ArH Phe), 8.24 (t, J = 5.6 Hz, 1H, NH), 9.26 (s, 1H, OH) 
ppm. 
13C NMR (100.6 MHz, DMSO): δ = 28.15 [C(CH3)3], 37.63 (CH2), 41.65 (CH2 Bzl), 55.89 (CH), 
78.02 [C(CH3)3], 114.94 (2CH), 126.17 (CH), 128.03 (2CH), 128.43 (2CH), 129.22 (2CH), 
139.35 (C), 138.15 (C), 155.23 (C), 156.19 (C=O), 171.47 (C=O) ppm. 
HRMS (ESI): m/z [M + H]+ calcd for C21H27N2O4: 371.19708; found: 371.19794. 
Synthesis of the dopamide of N-(tert-butyloxycarbonyl) phenyalanine, Boc-Phe-NH-Dopa, 13b 
Procedure D was followed using compound N-(tert-butyloxycarbonyl) phenylalanine (0.66 g, 
2.500 mmol) and dopamine hydrochloride to give compound 13b (0.91 g, 91%) as a white solid 
(from ethyl acetate/petroleum ether).  
1HNMR (400 MHz, CD3OCD3): δ = 1.36 (s, 9H, CH3 Boc), 2.61-2.64 (m, 2H, CH2 Dopa), 2.90-2.97 
(m, 1H, CH2), 3.12-3.17 (m, 1H, CH), 3.35-3.41 (m, 2H, CH2 Dopa), 4.32-4.38 (m, 1H, CH), 
6.01 (br. d, J = 7.6 Hz, 1H, NH), 6.54 (dd, J = 2.0 Hz, J = 8.0 Hz, 1H, ArH Dopa), 6.73 (d, J = 
2.0 Hz, 1H, ArH Dopa), 6.75 (d, J = 8.0 Hz, 1H, ArH Dopa), 7.20-7.31 (m, 6H, ArH Phe + NH), 
7.78 (br. s, 2H, OH) ppm. 
13C NMR (100.6 MHz, CD3OCD3): δ = 28.47 [C(CH3)3], 35.75 (CH2 Dopa), 39.14  (CH2), 41.74 
(CH2 Dopa), 56.72 (CH), 79.24 [C(CH3)3], 116.02 (CH), 116.55 (CH), 120.80 (CH), 127.13 (CH), 
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128.96 (2CH), 130.19 (2CH), 131.82 (C), 138.81 (C), 144.30 (C), 145.80 (C), 156.10 (C=O), 
171.93 (C=O) ppm. 
HRMS (ESI): m/z [M + H]+ calcd for C22H29N2O5: 401.20765; found: 401.20798. 
 
4.5.3. Synthesis of a hydroxyphenylamide of N-protocatechoyl dehydro-phenylalanine and 
phenylalanine 
Synthesis of the trifluorate of dehydrophenyalanine 4-hydroxybenzylamide, Tfa.H-Phe-NH-Bzl(4-
OH), 14a 
Procedure E was followed using compound 12a (0.66 g, 1.800 mmol) to give compound 14a 
(0.68 g, 99%) as a white solid (from diethyl ether). 
1HNMR (400 MHz, DMSO): δ = 4.18 (d, J = 6.4 Hz, 2H, CH2 Bzl), 6.67 (d, J = 8.4 Hz, 1H, ArH), 
7.00-7.05 (m, 3H, ArH), 7.12 (s, 1H, CH), 7.19-7.30 (m, 5H, ArH), 9.03 (t, J = 6.4 Hz, 1H, NH), 
9.29 (s, 1H, OH) ppm.  
13C NMR (100.6 MHz, DMSO): δ = 41.67 (CH2 Bzl), 114.95 (2CH), 126.66 (CH), 128.25 (2CH), 
128.73 (CH), 128.77 (2CH), 129.87 (2CH), 133.75 (C), 156.35 (C), 160.97 (C), 196.45 (C=O) 
ppm.  
Synthesis of the trifluorate of phenyalanine dopamine, Tfa.H-Phe-NH-Dopa, 14b 
Procedure E was followed using compound 12b (0.81 g, 2.000 mmol) to give compound 14b 
in quantitative yield as a yellow oil. 
1HNMR (400 MHz, DMSO): δ = 2.48-2.58 (m, 2H, CH2 Dopa), 3.22-3.27 (m, 2H, CH2 Dopa), 6.40 
(dd, J = 8.0 Hz, J = 2.0 Hz, 1H, ArH Dopa), 6.56 (d, J = 2.0 Hz 1H, ArH Dopa), 6.61 (d, J = 8.0 
Hz, 1H, ArH Dopa), 7.00 (s, 2H, ArH Phe), 7.13 (s, 2H, ArH Phe), 7.18-7.32 (m, 6H, ArH Phe + 
CH + NH + OH), 8.61 (t, J = 6.0 Hz, 1H, NH) ppm.  
13C NMR (100.6 MHz, DMSO): δ = 34.09 (CH2 Dopa), 40.67 (CH2 Dopa), 115.50 (CH), 115.91 
(CH), 119.17 (CH), 126.67 (CH), 128.29 (2CH), 128.73 (CH), 129.75 (C), 129.85 (2CH), 133.82 
(C), 143.61 (C), 145.10 (C), 160.87 (C), 196.38 (C=O) ppm. 
Synthesis of the 4-hydroxybenzylamide of N-protocatechoyl dehydrophenylalanine, Bz(3,4-OH)-
Phe-NH-Bzl(4-OH), 15a 
Procedure F was followed using compound 14a (0.19 g, 0.500 mmol) to give compound 15a 
(0.15 g, 75%) as a yellow oil. 
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1HNMR (400 MHz, CD3OCD3): δ = 2.42-2.48 (m, 2H, CH2 Bzl), 6.80 (d, J = 6.8 Hz, 2H, ArH), 7.13 
(d, J = 8.4 Hz, 2H, ArH), 7.25-7.36 (m, 6H, ArH), 7.41 (s, CH, Phe), 7.55-7.60 (m, 1H, ArH), 
7.76-7.78 (m, 1H, ArH) ppm. 
13C NMR (100.6 MHz, CD3OCD3): δ = 43.06 (CH2 Bzl), 115.67 (CH), 120.01 (CH), 125.08 (CH), 
125.78 (CH), 125.82 (CH), 127.11 (CH), 127.25 (CH), 127.78 (CH), 128.25 (CH), 128.42 (CH), 
128.69 (CH), 129.76 (CH), 129.85 (CH), 132.59 (C), 134.48 (C), 139.37 (C), 141.30 (C), 143.63 
(C), 155.50 (C), 159.74 (C), 170.41 (C=O), 171.88 (C=O) ppm. 
Synthesis of the trifluorate of phenyalanine 4-hydroxybenzylamide, Tfa.H-Phe-NH-Bzl(4-OH), 16a 
Procedure E was followed using compound 13a (0.74 g, 2.000 mmol) to give compound 16a 
(0.66 g, 85.2%) as a white solid. (from methanol/diethyl ether). M.p. 204.0-205.0 °C. 
1HNMR (400 MHz, DMSO): δ = 2.94-3.02 (m, 2H, CH2 Bzl), 3.96 (t, J = 7.2 Hz,1H, CH), 4.09 
(dd, J = 5.6 Hz, J = 8.8 Hz, 1H, CH), 4.20 (dd, J = 5.6 Hz, J = 8.8 Hz, 1H, CH), 6.66 (d, J = 
8.0 Hz, 2H, ArH Bzl), 6.89 (d, J = 8.0 Hz, 2H, ArH Bzl), 7.19 (d, J = 6.4 Hz, 2H, ArH Phe), 7.26-
7.34 (m, 3H, ArH Phe), 8.12 (br. s, 3H, NH3), 8.66 (t, J = 5.6 Hz, 1H, NH), 9.34 (s, 1H, OH) ppm. 
13C NMR (100.6 MHz, DMSO): δ = 37.12 (CH2), 41.98 (CH2 Bzl), 53.62 (CH), 115.04 (2CH), 
127.18 (CH), 128.11 (C), 128.57 (2CH), 128.85 (2CH), 129.48 (2CH), 134.88 (C), 156.50 (C), 
167.52 (C=O) ppm. 
Synthesis of the 4-hydroxybenzylamide of N-protocatechoyl phenylalanine, Bz(3,4-OH)-Phe-NH-
Bzl(4-OH), 17a 
Procedure F was followed using compound 16a (0.19 g, 0.500 mmol) to give compound 17a 
(0.131 g, 65%) as a light yellow solid. (from ethyl acetate/petroleum ether). 
1HNMR (400 MHz, CD3OCD3): δ = 2.95-3.08 (m, 2H, CH2 Bzl), 4.17 (d, J = 6.0 Hz, 2H, CH2 Phe), 
4.61-4.67 (m, 1H, CH), 6.66-6.73 (m, 2H, ArH), 6.71 (d, J = 8.4 Hz, 1H, ArH), 6.99-7.01 (m, 
2H, ArH), 7.14-7.31 (m, 7H, ArH), 8.15 (d, J = 8.4 Hz, 1H, NH), 8.36 (t, J = 6.0 Hz, 1H, NH), 
9.30 (br. s, 1H, OH) ppm. 
13C NMR (100.6 MHz, CD3OCD3): δ = 37.31 (CH2 Bzl), 41.67 (CH2), 54.92 (CH), 114.69 (CH), 
114.94 (2CH), 115.23 (CH), 119.26 (CH), 125.27 (C), 126.12 (CH), 128.01 (2CH), 128.44 
(2CH), 129.15 (2CH), 129.37 (C), 138.50 (C), 144.71 (C),  148.44 (C), 156.18 (C), 170.32 
(C=O), 171.36 (C=O) ppm. 
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4.5.4. Synthesis of the 4-hydroxybezylamide of a N-acyl dehydrotripeptide, Npx-Ala-Phe-
Phe-NH-Bzl(4-OH), 18a 
Procedure F was followed using Npx-Ala-Phe-OH (0.051 g, 0.113 mmol) and compound 16a 
to give compound 18a (0.056 g, 70% after chromatography) as a white solid. (from acetone/diethyl 
ether). M.p. 231.0-232.0 °C. 
1HNMR (400 MHz, CD3OCD3): δ = 1.42 (t, J = 7.2 Hz, 3H, CH3), 1.53 (t, J = 6.8 Hz, 3H, CH3 
Npx),  3.05 (dd, J = 10.4 Hz, J = 4.0 Hz, 1H, CH2 Bzl), 3.42 (dd, J = 4.0 Hz, J = 10.4 Hz, 1H, CH2 
Bzl), 3.89 (s, 3H, OCH3), 3.90-3.92 (m, 1H, CH Npx), 4.22-4.28 (m, 2H, CH2 Phe), 4.41 (dd, J 
= 6.4 Hz, J = 8.4 Hz, 1H, CH), 4.72-4.78 (m, 1H, CH), 6.79 (d, J = 8.8 Hz, 2H, ArH Bzl), 7.05 
(s, 1H, ArH), 7.07 (d, J = 2.4 Hz, 1H, ArH), 7.13 (d, J = 2.4 Hz, 1H, ArH), 7.16-7.34 (m, 12H, 
ArH), 7.54 (dd, J = 4.8 Hz, J = 4.0 Hz, 2H, ArH), 7.64 (d, J = 1.2 Hz, 1H, ArH), 7.72 (d, J = 8.4 
Hz, 1H, NH), 7.83 (br. t, J = 6.0 Hz, 1H, NH), 7.93 (d, J = 4.0 Hz, 1H, NH), 8.23 (s, 1H, NH), 
8.52 (s, 1H, OH) ppm. 
13C NMR (100.6 MHz, CD3OCD3): δ = 16.67 (CH3), 19.21 (CH3 Npx), 37.99 (CH2 Bzl), 43.07 
(CH2), 46.60 (CH Npx), 52.21 (CH), 55.58 (OCH3), 56.26 (CH), 106.45 (CH), 115.85 (2CH), 
119.61 (CH), 126.75 (CH), 127.01 (CH), 127.02 (CH), 128.01 (CH), 129.10 (2CH), 129.27 
(2CH), 129.53 (C), 129.57 (CH), 129.70 (2CH), 129.76 (C), 129.84 (2CH), 129.96 (CH), 130.02 
(CH), 130.27 (2CH), 131.18 (C), 134.62 (C), 134.66 (C), 137.54 (C), 139.68 (C),  157.21 (C), 
158.55 (C), 164.92 (C=O), 171.55 (C=O), 174.44 (C=O), 176.68 (C=O) ppm. 
HRMS (ESI): m/z [M + H]+ calcd for C42H43N4O6: 699.31826; found: 699.31835. 
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